Professor Glenda Halliday

NHMRC Senior Principal Research Fellow
Central Clinical School

Telephone +61 2 9351 0888

Map

Biographical details

I received my degrees at the University of New South Wales, postdoctoral training at Flinders University of South Australia prior to Australian Research Council (ARC) Queen Elizabeth II and National Health & Medical Research Council (NHMRC) research fellowships, joining NeuRA in 1993 and The University of Sydney in 2016. I have >400 publications from many successfully completed competitive research grants, andlead a research program of ~70 researchers tackling non-Alzheimer's neurodegeneration.

Research interests

I work on identifying and understanding the pathobiology of non-Alzheimer dementias and degenerative motor syndromes, as these syndromes are currently under-recognized, mainly affect people in their prime, can kill rapidly, and have no mechanistic therapies. I lead a large research team that uses clinical, patient-derived, and experimental models to progress knowledge on these diseases.

My research has highlighted broader pathological involvement in Parkinson's disease and especially in dementia with Lewy bodies, with recent work suggesting lysosome dysfunction and immunity are involved. In the non-Alzheimer frontotemporal dementias, the firstlarge scale studies were initiated in my laboratory and form the basis for both pathological and clinical staging of these syndromes, with recent work targeting their biological basis. My vision is to continue to develop significant research capacity in non-Alzheimer dementias and motor syndromes, and to coalesce Australian research capacity in these areas so that significant medical advances can be made.

Current projects

Frontotemporal dementia and motor neurodegenerative syndromes

This program of research facilitates and enhances collaboration between internationally-recognised leaders working on the clinical, pathological and biological characteristics of frontotemporal dementia and motor neurodegenerative syndromes. Frontotemporal and motor neurodegeneration cause a group of disorders identified by distinct clinical signs and symptoms, and/or specific histopathologies. These disorders are generally rapidly progressing (median survival 1-3 years from diagnosis), cause behavioural, language or motor deficits (often in combination), and together are a leading cause of dementia (particularly in people aged <65 years). They are unified by the focal and selective nature of the neurodegeneration, which largely occurs in association with the abnormal aggregation of one of three distinct proteins (tau, TDP43, FUS) in neurons and/or glia. For most patients their clinical presentations relate to the brain region affected rather than the underlying proteinopathy. This program unites the diverse research of the investigators to focus on crucial, understudied research areas; 1) the pathogenesis and selectivity of degeneration; 2) the characterisation and mechanisms of disease progression, 3) differences in toxicity of the proteins involved, 4) the development of in vivo biomarkers to detect the different proteinopathies, and 5) novel treatment approaches.

Non-Alzheimer’s disease degenerative dementias: Identifying prodromal genetic/familial phenotypes, modifying factors, and protein variations involved in progression

Background: Non-Alzheimer's disease (AD) dementias, including those overlapping with AD, occur in more than 50% of dementia patients. In those without overlapping AD, most have pathology consistent with a frontotemporal dementia (FTD) syndrome, motor neuron disease (MND) or Lewy body disease, including Parkinson’s disease (LBD). Clinical diagnostic schemas for dementia largely identify individuals with advanced disease, at a point where disease modifying therapies will be less effective. In 2014, diagnostic criteria for preclinical AD were defined to allow better therapeutic targeting. A similar approach is required for the non-AD dementias.

Need: Identification of preclinical forms of FTD and LBD is required, in addition to identifying the different protein species involved in the various non-AD phenotypes for therapeutic targeting.

Strategy:

1) Screen well-defined Australian cohorts of FTD, MND and LBD to recruit and study families with genetic forms of these disorders (presymptomatic and symptomatic mutation carriers to be compared with non-carriers)

2) phenotype clinical, imaging (structural & amyloid/tau) and biological fluid (blood, saliva, urine, CSF) proteins and determine patterns of change over time

3) identify propagation/progression of the proteinopathies and biomarker validation

4) assess modifying factors

5) database all information

6) develop preclinical/early clinical diagnostic criteria

Neuronal toll-like 2 receptors contribute to the spread of Parkinson's disease

Parkinson’s disease is the most common progressive neurodegenerative movement disorder, with 30 new cases diagnosed per day in Australia. The clinical course for many patients is long and slow, often occurring over decade/s producing considerable health-related expenditures. Underlying this long, slow

disease course is the slow infiltration of the diagnostic neuronal inclusion pathologies in a characteristic disease pattern through the brain. In 2008 the concept that the disease spread from cell to cell took hold following the identification of inclusions in foetal neurons grafted therapeutically into patients with PD. Mounting evidence suggests the mechanism for this phenomenon includes the release of α-synuclein aggregates from a host cell to be taken-up by neighbouring cells and recent work in glia has shown uptake of toxic α-synuclein species is via toll-like 2 receptors (TLR2). We hypothesise that toxic α-synuclein is taken up by neurons through activating TLR2, propagating the α-synuclein pathology from one neuron to the next, and will use unique human tissue resources (staged brain tissue from PD patients, iPS derived human neurons), transgenic mice (TLR2 knock-out) and neuronal cell lines to assess this theory.

Are there peripheral changes in GBA protein/activity in idiopathic Parkinson’s disease patients?

Differences in the part of peoples DNA that makes the glucocerebrosidase (GBA) protein are the most frequent known genetic risk factor for Parkinson’s disease. In the brain of Parkinson’s disease patients, glucocerebrosidase protein is reduced. We want to know if glucocerebrosidase is also reduced outside of the brain, in blood cells of Parkinson’s disease patients. If so, could this be an early test for Parkinson’s disease? Our study aims to determine whether glucocerebrosidase protein is reduced in white blood cells from Parkinson’s disease patients. We will collect blood samples from Parkinson’s disease patients and matched control subjects and measure the glucocerebrosidase protein using a technique known as flow cytometry.

Associations

I am on the editorial boards of 5 international journals, and on the Scientific Advisory Boards for a number of international organizations and research institutes. I was elected president of the Australian Neuroscience Society (ANS 2006-2007), appointed to the NHMRC Academy (2009, 2011) and ARC College of Experts (2013).

Awards and honours

I was awarded the 2011 Nina Kondelos Prize for outstanding neuroscience from ANS, named a high achiever in Australian Health and Medical Research by NHMRC (http://www.nhmrc.gov.au/high-achievers/biographies) and awarded a Fellowship of the Australian Academy of Health and Medical Sciences.

Selected grants

2018

  • Frontotemporal dementia and motor neurodegenerative syndromes; Halliday G, Halliday G, Mattick J, Hodges J, Hodges J, Kiernan M, Piguet O, Piquet O, Kril J, Ittner L, Ittner L, Kassiou M; National Health and Medical Research Council (NHMRC)/Program Grants.

2017

  • Utilising novel biomarkers to develop predictors of neurodegeneration; Lewis S, Halliday G; DVC Research/Sydney Research Excellence Initiative 2020 (SREI).
  • Peripheral Inflammatory cytokine profiling in Parkinson�s disease; Dzamko N, Halliday G; Michael J Fox Foundation for Parkinsons Research/Research Support.
  • Is ATXN2 a potential therapeutic target in MND?; Tan R, Halliday G, Kiernan M; Motor Neurone Disease Research Institute of Australia/Grants in aid.
  • COQ2 mutation and methylation dysfunction leading to a-synuclein pathology; Kim W, Halliday G; Multiple System Atrophy Coalition/Seed Grant.

2016

  • Confocal Microscopes - live cell imaging and routine scanning; Halliday G, Valenzuela M, Arnold J; DVC Research/Equipment Grant.
  • Are their peripheral changes in GBA protein/activity in idiopathic Parkinson's disease patients; Halliday G; Michael J Fox Foundation for Parkinsons Research/Research Support.
  • Neuronal toll-like 2 receptors contribute to the spread of Parkinson's disease; Halliday G, Halliday G, Dzamko N, Daher J, Sue C; National Health and Medical Research Council (NHMRC)/Project Grants.

2015

  • Non-Alzheimer's disease degenerative dementias: Identifying prodromal genetic/familial phenotypes, modifying factors, and protein variations involved in progression; Halliday G, Hodges J, Lewis S, Piquet O, Kril J, Kwok J, Villemagne V, Kiernan M, Rowe D, McKeith I; National Health and Medical Research Council (NHMRC)/Dementia Research Team Grants.
  • Tackling the complex pathogenesis of non-Alzheimer dementias and motor neurodegenerative disorders; Halliday G; National Health and Medical Research Council (NHMRC)/Research Fellowships.

2013

  • Frontotemporal dementia and motor neurodegenerative syndromes; Halliday G, Gotz J, Ittner L, Kril J, Hodges J, Kiernan M; National Health and Medical Research Council (NHMRC)/Program Grants.

2009

  • Pathogenic mechanisms common to all subtypes of frontotemporal dementia; Kril J, Ittner L, Goetz J, Halliday G; National Health and Medical Research Council (NHMRC)/Project Grants.

2005

  • The role of neutral amino acid transport in normal physiology; Rasko J, Bröer S, Halliday G, Pollard J, Broeer S; Australian Research Council (ARC)/Discovery Projects (DP).

2004

  • Understanding variation in frontotemporal dementia; Kril J, Hodges J, Creasey H, Halliday G, Hodges J; National Health and Medical Research Council (NHMRC)/Project Grants.

Selected publications

Download citations: PDF RTF Endnote

Book Chapters

  • Lewis, S., Shine, J., Brooks, D., Halliday, G. (2015). Hallucinogenic mechanisms: Pathological and pharmacological insights. In Daniel Collerton, Urs Peter Mosimann, Elaine Perry (Eds.), The Neuroscience of Visual Hallucinations, (pp. 121-149). Oxford: John Wiley & Sons. [More Information]
  • Stevens, C., Halliday, G. (2014). The role of astrocytes in parkinson's disease. Inflammation in Parkinson's Disease: Scientific and Clinical Aspects, (pp. 127-144). Cham: Springer International Publishing Switzerland. [More Information]
  • Dickson, P., Shehadeh, J., Double, K., Bobrovskaya, L., Reyes, S., Dunkley, P., Halliday, G. (2013). Analysis of Tyrosine Hydroxylase Isoforms and Phosphorylation in Parkinson's Disease. In Lee E. Eiden (Eds.), Catecholamine Research in the 21st Century: Abstracts and Graphical Abstracts, 10th International Catecholamine Symposium, 2012, (pp. 15-15). London: Elsevier. [More Information]
  • Double, K., Halliday, G., Reyes, S. (2012). Substantia Nigra, Ventral Tegmental Area and Retrorubral Fields. In Juergen K. Mai and George Paxinos (Eds.), The Human Nervous System, (pp. 439-455). London: Academic Press.
  • Halliday, G., Reyes, S., Double, K. (2012). Substantia Nigra, Ventral Tegmental Area, and Retrorubral Fields. In Juergen K. Mai and George Paxinos (Eds.), The Human Nervous System, (pp. 439-455). London: Academic Press. [More Information]
  • Kril, J., Karlstrom, H., Brooks, W., Kwok, J., Halliday, G., Schofield, P. (2005). Variable phenotype of Alzheimer's disease with spastic paraparesis. In Cummings J; Hardy J; Poncet M; Christen Y (Eds.), Genotype-Proteotype-Phenotype Relationships in Neurodegenerative Disease, (pp. 166). Berlin: Springer.
  • Kril, J., Hodges, J., Davies, R., Du, N., Halliday, G. (2004). Survival In Frontotemporal Dementia. In B Vellas, LJ Fitten, B Winblad, H Feldman, M Grundman, E Giacobini (Eds.), Research and practice in Alzheimers disease, (pp. 215-219). Paris, New York: Springer.
  • Kril, J., Patel, S., Harding, A., Halliday, G. (2003). Hippocampal neuron loss in vascular dementia and Alzheimer's disease. In B. Vellas, L. J. Fitten, B. Winblad, H. Feldman, M. Grundman & E. Giacobini (Eds.), Research and Practice in Alzheimers Disease, Volume 7, (pp. 199-203). NY: Springer Publishing Company.
  • Morris, J., Hely, M., Halliday, G. (2003). Parkinsonism and Ageing. In Perminder s. Sachdev (Eds.), The Ageing Brain: The Neurobiology and Neuropsychiatry of Ageing, (pp. 275-282). Lisse, The Netherlands: Swets and Zeitlinger Publishers.

Journals

  • Tan, R., Ke, Y., Ittner, L., Halliday, G. (2017). ALS/FTLD: experimental models and reality. Acta Neuropathologica, 133(2), 177-196. [More Information]
  • Kirik, D., Cederfjall, E., Halliday, G., Petersen, A. (2017). Gene therapy for Parkinson's disease: Disease modification by GDNF family of ligands. Neurobiology of Disease, 97, 179-188. [More Information]
  • Ahmed, R., Irish, M., van Eersel, J., Ittner, A., Ke, Y., Volkerling, A., van der Hoven, J., Tanaka, K., Karl, T., Kassiou, M., Kril, J., Piguet, O., Kiernan, M., Halliday, G., Hodges, J., et al (2017). Mouse models of frontotemporal dementia: A comparison of phenotypes with clinical symptomatology. Neuroscience and Biobehavioral Reviews, 74(1 March 2017), 126-138. [More Information]
  • Landeck, N., Hall, H., Ardah, M., Majbour, N., El-Agnaf, O., Halliday, G., Kirik, D. (2016). A novel multiplex assay for simultaneous quantification of total and S129 phosphorylated human alpha-synuclein. Molecular Neurodegeneration, 11(1), 61. [More Information]
  • Fu, Y., Hsiao, J., Paxinos, G., Halliday, G., Kim, W. (2016). ABCA7 Mediates Phagocytic Clearance of Amyloid-beta in the Brain. Journal of Alzheimer's Disease, 54(2), 569-584. [More Information]
  • Kovacs, G., Ferrer, I., Grinberg, L., Alafuzoff, I., Attems, J., Budka, H., Cairns, N., Crary, J., Halliday, G., Kril, J., et al (2016). Aging-related tau astrogliopathy (ARTAG): harmonized evaluation strategy. Acta Neuropathologica, 131(1), 87-102. [More Information]
  • Ahmed, R., Irish, M., Piguet, O., Halliday, G., Ittner, L., Farooqi, S., Hodges, J., Kiernan, M. (2016). Amyotrophic lateral sclerosis and frontotemporal dementia: distinct and overlapping changes in eating behaviour and metabolism. The Lancet Neurology, 15(3), 332-342. [More Information]
  • Bleasel, J., Halliday, G., Kim, W. (2016). Animal modeling an oligodendrogliopathy - multiple system atrophy. Acta Neuropathologica Communications, 4(1), 1-15. [More Information]
  • O'Callaghan, C., Hornberger, M., Balsters, J., Halliday, G., Lewis, S., Shine, J. (2016). Cerebellar atrophy in Parkinson's disease and its implication for network connectivity. Brain, 139(Pt 3), 845-855. [More Information]
  • Tan, R., Kril, J., McGinley, C., Hassani, M., Masuda-Suzukake, M., Hasegawa, M., Mito, R., Kiernan, M., Halliday, G. (2016). Cerebellar neuronal loss in Amyotrophic Lateral Sclerosis cases with ATXN2 intermediate repeat expansions. Annals of Neurology, 79(2), 295-305. [More Information]
  • Chen, B., Mills, J., Takenaka, K., Bliim, N., Halliday, G., Janitz, M. (2016). Characterization of circular RNAs landscape in multiple system atrophy brain. Journal of Neurochemistry, 139(3), 485-496. [More Information]
  • Ahmed, R., Caga, J., Devenney, E., Hsieh, S., Bartley, L., Highton-Williamson, E., Ramsey, E., Zoing, M., Halliday, G., Piguet, O., Kiernan, M., et al (2016). Cognition and eating behavior in amyotrophic lateral sclerosis: effect on survival. Journal of Neurology, 263(8), 1593-1603. [More Information]
  • Weissleder, C., Fung, S., Wong, M., Barry, G., Double, K., Halliday, G., Webster, M., Weickert, C. (2016). Decline in proliferation and immature neuron markers in the human subependymal zone during aging: Relationship to EGF- and FGF-related transcripts. Frontiers in Aging Neuroscience, 8. [More Information]
  • Leyton, C., Britton, A., Hodges, J., Halliday, G., Kril, J. (2016). Distinctive pathological mechanisms involved in primary progressive aphasias. Neurobiology of Aging, 38, 82-92. [More Information]
  • Burrell, J., Forrest, S., Bak, T., Hodges, J., Halliday, G., Kril, J. (2016). Expanding the phenotypic associations of globular glial tau subtypes. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring, 4, 6-13. [More Information]
  • Schott, J., Crutch, S., Carrasquillo, M., Uphill, J., Shakespeare, T., Ryan, N., Yong, K., Lehmann, M., Ertekin-Taner, N., Halliday, G., et al (2016). Genetic risk factors for the posterior cortical atrophy variant of Alzheimer's disease. Alzheimer's and Dementia, 12(8), 862-871. [More Information]
  • Guerreiro, R., Escott-Price, V., Darwent, L., Parkkinen, L., Ansorge, O., Hernandez, D., Nalls, M., Clark, L., Honig, L., Halliday, G., et al (2016). Genome-wide analysis of genetic correlation in dementia with Lewy bodies, Parkinson's and Alzheimer's diseases. Neurobiology of Aging, 38, 214.e7-214.e10. [More Information]
  • Van der Jeugd, A., Vermaercke, B., Halliday, G., Staufenbiel, M., Gotz, J. (2016). Impulsivity, decreased social exploration, and executive dysfunction in a mouse model of frontotemporal dementia. Neurobiology of Learning and Memory, 130, 34-43. [More Information]
  • Dzamko, N., Rowe, D., Halliday, G. (2016). Increased peripheral inflammation in asymptomatic leucine-rich repeat kinase 2 mutation carriers. Movement Disorders, 31(6), 889-897. [More Information]
  • Perera, G., Ranola, M., Rowe, D., Halliday, G., Dzamko, N. (2016). Inhibitor treatment of peripheral mononuclear cells from Parkinson's disease patients further validates LRRK2 dephosphorylation as a pharmacodynamic biomarker. Scientific Reports, 6, 1-8. [More Information]
  • Matrone, C., Dzamko, N., Madsen, P., Nyegaard, M., Pohlmann, R., Sondergaard, R., Lassen, L., Andresen, T., Halliday, G., et al (2016). Mannose 6-phosphate receptor is reduced in -synuclein overexpressing models of parkinsons disease. PloS One, 11(8), 1-21. [More Information]
  • Wang, G., Huang, Y., Wang, L., Zhang, Y., Xu, J., Zhou, Y., Lourenco, G., Zhang, B., Halliday, G., et al (2016). MicroRNA-146a suppresses ROCK1 allowing hyperphosphorylation of tau in Alzheimer's disease. Scientific Reports, 6, 1-12. [More Information]
  • Shibuya, K., Park, S., Geevasinga, N., Menon, P., Howells, J., Simon, N., Huynh, W., Noto, Y., Gotz, J., Kril, J., Vucic, S., Kiernan, M., et al (2016). Motor cortical function determines prognosis in sporadic ALS. Neurology, 87(5), 513-520. [More Information]
  • Ahmed, R., Devenney, E., Irish, M., Ittner, A., Naismith, S., Ittner, L., Rohrer, J., Halliday, G., Eisen, A., Hodges, J., Kiernan, M. (2016). Neuronal network disintegration: common pathways linking neurodegenerative diseases. Journal of Neurology, Neurosurgery and Psychiatry, 87(11), 1234-1241. [More Information]
  • McCann, H., Cartwright, H., Halliday, G. (2016). Neuropathology of alpha-synuclein propagation and braak hypothesis. Movement Disorders, 31(2), 152-160. [More Information]
  • Hu, Y., Zou, Y., Huang, Y., Zhang, Y., Lourenco, G., Chen, S., Halliday, G., Wang, G., Ren, R. (2016). ROCK1 Is Associated with Alzheimer's Disease-Specific Plaques, as well as Enhances Autophagosome Formation But not Autophagic A-Beta Clearance. Frontiers in Cellular Neuroscience, 10, 1-11. [More Information]
  • Coupland, K., Kim, W., Halliday, G., Hallupp, M., Dobson-Stone, C., Kwok, J. (2016). Role of the long non-coding RNA MAPT-AS1 in regulation of microtubule associated protein tau (MAPT) expression in Parkinson's disease. PloS One, 11(6). [More Information]
  • Lobo, E., Delic (nee Roue), N., Richardson, A., Raviraj, V., Halliday, G., Di Girolamo, N., Myerscough, M., Lyons, G. (2016). Self-organized centripetal movement of corneal epithelium in the absence of external cues. Nature Communications, 7, 1-8. [More Information]
  • Mills, J., Ward, M., Kim, W., Halliday, G., Janitz, M. (2016). Strand-specific RNA-sequencing analysis of multiple system atrophy brain transcriptome. Neuroscience, 322, 234-250. [More Information]
  • Halliday, G., Kiernan, M., Kril, J., Mito, R., Masuda-Suzukake, M., Hasegawa, M., McCann, H., Bartley, L., Dobson-Stone, C., Kwok, J., et al (2016). TDP-43 in the hypoglossal nucleus identifies amyotrophic lateral sclerosis in behavioral variant frontotemporal dementia. Journal of the Neurological Sciences, 366, 197-201. [More Information]
  • Burrell, J., Halliday, G., Kril, J., Ittner, L., Gotz, J., Kiernan, M., Hodges, J. (2016). The frontotemporal dementia-motor neuron disease continuum. The Lancet, 388(10047), 919-931. [More Information]
  • Fu, Y., Paxinos, G., Watson, C., Halliday, G. (2016). The substantia nigra and ventral tegmental dopaminergic neurons from development to degeneration. Journal of Chemical Neuroanatomy, 76, 98-107. [More Information]
  • Wang, G., Huang, Y., Chen, W., Chen, S., Wang, Y., Xiao, Q., Liu, J., Fung, V., Halliday, G., Chen, S. (2016). Variants in the SNCA gene associate with motor progression while variants in the MAPT gene associate with the severity of Parkinson's disease. Parkinsonism and Related Disorders, 24, 89-94. [More Information]
  • Leshchyns'ka, I., Liew, H., Shepherd, C., Halliday, G., Stevens, C., Ke, Y., Ittner, L., Sytnyk, V. (2015). A beta-dependent reduction of NCAM2-mediated synaptic adhesion contributes to synapse loss in Alzheimer's disease. Nature Communications, 6, 1-18. [More Information]
  • Fu, Y., Hsiao, J., Paxinos, G., Halliday, G., Kim, W. (2015). ABCA5 Regulates amyloid-beta peptide production and is associated with Alzheimer's disease neuropathology. Journal of Alzheimer's Disease, 43(3), 857-869. [More Information]
  • Shine, J., Muller, A., O'Callaghan, C., Hornberger, M., Halliday, G., Lewis, S. (2015). Abnormal connectivity between the default mode and the visual system underlies the manifestation of visual hallucinations in Parkinson's disease: a task-based fMRI study. NPJ Parkinson's Disease, 1, 1-8. [More Information]
  • Yang, Y., Shepherd, C., Halliday, G. (2015). Aneuploidy in Lewy body diseases. Neurobiology of Aging, 36(3), 1253-1260. [More Information]
  • Rusznak, Z., Kim, W., Hsiao, J., Halliday, G., Paxinos, G., Fu, Y. (2015). Early in vivo effects of the human mutant amyloid-? protein precursor (hA?PPSwInd) on the mouse olfactory bulb. Journal of Alzheimer's Disease, 49(2), 443-457. [More Information]
  • Ahmed, R., Latheef, S., Bartley, L., Irish, M., Halliday, G., Kiernan, M., Hodges, J., Piguet, O. (2015). Eating behavior in frontotemporal dementia. Neurology, 85(15), 1310-1317. [More Information]
  • Coupland, K., Kim, W., Halliday, G., Hallupp, M., Dobson-Stone, C., Kwok, J. (2015). Effect of PSEN1 mutations on MAPT methylation in early-onset Alzheimer�s disease. Current Alzheimer Research, 12(8), 745-751.
  • Prusiner, S., Woerman, A., Mordes, D., Watts, J., Rampersaud, R., Berry, D., Patel, S., Oehler, A., Lowe, J., Kravitz, S., et al (2015). Evidence for alpha-synuclein prions causing multiple system atrophy in humans with parkinsonism. Proceedings of the National Academy of Sciences of the United States of America (PNAS), 112(38), E5308-E5317. [More Information]
  • Abbott, S., Jenner, A., Spiro, A., Batterham, M., Halliday, G., Garner, B. (2015). Fatty acid composition of the anterior cingulate cortex indicates a high susceptibility to lipid peroxidation in Parkinson's disease. Journal of Parkinson's Disease, 5(1), 175-185. [More Information]
  • Forrest, S., Kril, J., Halliday, G. (2015). Frontotemporal lobar degeneration with tau inclusions (FTLD-tau): Recent developments in pathology and pathogenesis. Australian Biochemist, 46(1), 8-11.
  • Ittner, L., Halliday, G., Kril, J., Gotz, J., Kiernan, M. (2015). FTD and ALS-translating mouse studies into clinical trials. Nature Reviews. Neurology, 11(6), 360-366. [More Information]
  • Mills, J., Kavanagh, T., Kim, W., Chen, B., Waters, P., Halliday, G., Janitz, M. (2015). High expression of long intervening non-coding RNA OLMALINC in the human cortical white matter is associated with regulation of oligodendrocyte maturation. Molecular Brain Research, 8(1), 1-12. [More Information]
  • Dzamko, N., Geczy, C., Halliday, G. (2015). Inflammation is genetically implicated in Parkinson's disease. Neuroscience, 302, 89-102. [More Information]
  • Dobson-Stone, C., Shaw, A., Hallupp, M., Bartley, L., McCann, H., Brooks, W., Loy, C., Schofield, P., Halliday, G., et al (2015). Is CHCHD10 Pro34Ser pathogenic for frontotemporal dementia and amyotrophic lateral sclerosis? Brain, 138(10), e385-e385. [More Information]
  • Mills, J., Chen, J., Kim, W., Waters, P., Prabowo, A., Aronica, E., Halliday, G., Janitz, M. (2015). Long intervening non-coding RNA 00320 is human brain-specific and highly expressed in the cortical white matter. Neurogenetics, 16(3), 201-213. [More Information]
  • Lourenco, G., Janitz, M., Huang, Y., Halliday, G. (2015). Long noncoding RNAs in TDP-43 and FUS/TLS-related frontotemporal lobar degeneration (FTLD). Neurobiology of Disease, 82, 445-454. [More Information]
  • Murphy, K., Gysbers, A., Abbott, S., Spiro, A., Furuta, A., Cooper, A., Garner, B., Kabuta, T., Halliday, G. (2015). Lysosomal-associated membrane protein 2 isoforms are differentially affected in early Parkinson's disease. Movement Disorders, 30(12), 1639-1647. [More Information]
  • Postuma, R., Berg, D., Stern, M., Poewe, W., Olanow, C., Oertel, W., Obeso, J., Marek, K., Litvan, I., Lang, A., et al (2015). MDS clinical diagnostic criteria for Parkinson's disease. Movement Disorders, 30(12), 1591-1601. [More Information]
  • Berg, D., Postuma, R., Adler, C., Bloem, B., Chan, P., Dubois, B., Gasser, T., Goetz, C., Halliday, G., et al (2015). MDS research criteria for prodromal Parkinson's disease. Movement Disorders, 30(12), 1600-1609. [More Information]
  • Cairns, N., Perrin, R., Franklin, E., Carter, D., Vincent, B., Xie, M., Bateman, R., Benzinger, T., Friedrichsen, K., Halliday, G., et al (2015). Neuropathologic assessment of participants in two multi-center longitudinal observational studies: The Alzheimer Disease Neuroimaging Initiative (ADNI) and the Dominantly Inherited Alzheimer Network (DIAN). Neuropathology, 35(4), 390-400. [More Information]
  • Duyckaerts, C., Braak, H., Brion, J., Buee, L., Del Tredici, K., Goedert, M., Halliday, G., Neumann, M., Spillantini, M., et al (2015). PART is part of Alzheimer disease. Acta Neuropathologica, 129(5), 749-756. [More Information]
  • Devenney, E., Bartley, L., Hoon, C., O'Callaghan, C., Kumfor, F., Hornberger, M., Kwok, J., Halliday, G., Kiernan, M., Piguet, O., et al (2015). Progression in Behavioral Variant Frontotemporal Dementia: A Longitudinal Study. JAMA Neurology, 72(12), 1501-1509. [More Information]
  • Halliday, G. (2015). Progressive supranuclear palsy finally has a clinically measureable Ͽ abnormality. Journal of Neurology, Neurosurgery and Psychiatry, 86(3), 241-241. [More Information]
  • Helmfors, L., Boman, A., Civitelli, L., Nath, S., Sandin, L., Janefjord, C., McCann, H., Zetterberg, H., Blennow, K., Halliday, G., et al (2015). Protective properties of lysozyme on beta-amyloid pathology: Implications for Alzheimer disease. Neurobiology of Disease, 83, 122-133. [More Information]
  • Halliday, G. (2015). Re-evaluating the glio-centric view of multiple system atrophy by highlighting the neuronal involvement. Brain, 138(Pt 8), 2116-2119. [More Information]
  • Halliday, G., Murphy, K. (2015). Reply: Lysosomal dysfunction in Parkinson's disease. Anatomy and Embryology (Brain Structure and Function), 138(4), e340. [More Information]
  • McCann, H., McGeachie, A., Silberstein, P., Lewis, S., Halliday, G. (2015). Restricted disease propagation in multiple system atrophy with prolonged survival. Neuropathology and Applied Neurobiology, 41(5), 681-685. [More Information]
  • Gabery, S., Halliday, G., Kirik, D., Englund, E., Petersen, A. (2015). Selective loss of oxytocin and vasopressin in the hypothalamus in early Huntington disease: a case study. Neuropathology and Applied Neurobiology, 41(6), 843-848. [More Information]
  • Cheshire, P., Ayton, S., Bertram, K., Ling, H., Li, A., McLean, C., Halliday, G., O'Sullivan, S., Revesz, T., Finkelstein, D., et al (2015). Serotonergic markers in Parkinson's disease and levodopa-induced dyskinesias. Movement Disorders, 30(6), 796-804. [More Information]
  • Ke, Y., Hummel, A., Stevens, C., Gladbach, A., Ippati, S., Bi, M., Lee, W., Halliday, G., Haass, N., Kiernan, M., et al (2015). Short-term suppression of A315T mutant human TDP-43 expression improves functional deficits in a novel inducible transgenic mouse model of FTLD-TDP and ALS. Acta Neuropathologica, 130(5), 661-678. [More Information]
  • Huang, Y., Wang, G., Rowe, D., Wang, Y., Kwok, J., Xiao, Q., Mastaglia, F., Liu, J., Chen, S., Halliday, G. (2015). SNCA gene, but not MAPT, influences onset age of Parkinson's Disease in Chinese and Australians. BioMed Research International, 2015, 1-6. [More Information]
  • Fatima, M., Tan, R., Halliday, G., Kril, J. (2015). Spread of pathology in amyotrophic lateral sclerosis: assessment of phosphorylated TDP-43 along axonal pathways. Acta Neuropathologica Communications, 3(1), 1-9. [More Information]
  • Tan, R., Kril, J., Fatima, M., McGeachie, A., McCann, H., Shepherd, C., Forrest, S., Affleck, A., Kwok, J., Hodges, J., Kiernan, M., et al (2015). TDP-43 proteinopathies: pathological identification of brain regions differentiating clinical phenotypes. Brain, 138(10), 3110-3122. [More Information]
  • Tan, R., Devenney, E., Kiernan, M., Halliday, G., Hodges, J., Hornberger, M. (2015). Terra incognita-cerebellar contributions to neuropsychiatric and cognitive dysfunction in behavioral variant frontotemporal dementia. Frontiers in Aging Neuroscience, 7, 1-9. [More Information]
  • Cordato, N., Halliday, G. (2015). The differentiation of progressive supranuclear palsy. Neurodegenerative Disease Management, 5(5), 385-388. [More Information]
  • Szeto, J., O’Callaghan, C., Shine, J., Walton, C., Mowszowski, L., Naismith, S., Halliday, G., Lewis, S. (2015). The relationships between mild cognitive impairment and phenotype in Parkinson’s disease. NPJ Parkinson's Disease, 1. [More Information]
  • Chen, J., Mills, J., Halliday, G., Janitz, M. (2015). The role of transcriptional control in multiple system atrophy. Neurobiology of Aging, 36(1), 394-400. [More Information]
  • Mills, J., Kim, W., Halliday, G., Janitz, M. (2015). Transcriptome analysis of grey and white matter cortical tissue in multiple system atrophy. Neurogenetics, 16(2), 107-122. [More Information]
  • McCann, H., Fung, V., Klein, C., Halliday, G. (2015). Unusual a-synuclein and cerebellar pathologies in a case of hereditary myoclonus-dystonia without SGCE mutation. Neuropathology and Applied Neurobiology, 41(6), 837-842. [More Information]
  • Shine, J., Mills, J., Qui, J., O'Callaghan, C., Terpening, Z., Halliday, G., Naismith, S., Lewis, S. (2015). Validation of the Psychosis and Hallucinations Questionnaire in Non-demented Patients with Parkinson’s Disease. Movement Disorders Clinical Practice, 2(2), 175-181. [More Information]
  • McCann, H., Stevens, C., Cartwright, H., Halliday, G. (2014). a-Synucleinopathy phenotypes. Parkinsonism and Related Disorders, 20(SUPPL.1), S62-S67. [More Information]
  • Kim, W., Kagedal, K., Halliday, G. (2014). Alpha-synuclein biology in Lewy body diseases. Alzheimers Research & Therapy, 6(1), 1-9. [More Information]
  • Abbott, S., Li, H., Munoz, S., Knoch, B., Batterham, M., Murphy, K., Halliday, G., Garner, B. (2014). Altered ceramide acyl chain length and ceramide synthase gene expression in Parkinson's disease. Movement Disorders, 29(4), 518-526. [More Information]
  • Don, A., Hsiao, J., Bleasel, J., Couttas, T., Halliday, G., Kim, W. (2014). Altered lipid levels provide evidence for myelin dysfunction in multiple system atrophy. Acta Neuropathologica Communications, 2, 1-14. [More Information]
  • Tan, R., Wong, S., Kril, J., Piguet, O., Hornberger, M., Hodges, J., Halliday, G. (2014). Beyond the temporal pole: Limbic memory circuit in the semantic variant of primary progressive aphasia. Brain, 137(7), 2065-2076. [More Information]
  • Ahmed, R., Paterson, R., Warren, J., Zetterberg, H., O'Brien, J., Fox, N., Halliday, G., Schott, J. (2014). Biomarkers in dementia: Clinical utility and new directions. Journal of Neurology, Neurosurgery and Psychiatry, 85(12), 1426-1434. [More Information]
  • Mahul-Mellier, A., Fauvet, B., Gysbers, A., Dikiy, I., Oueslati, A., Georgeon, S., Lamontanara, A., Bisquertt, A., Eliezer, D., Masliah, E., et al (2014). C-Abl phosphorylates a-synuclein and regulates its degradation: Implication for a-synuclein clearance and contribution to the pathogenesis of parkinson's disease. Human Molecular Genetics, 23(11), 2858-2879. [More Information]
  • Tan, R., Devenney, E., Dobson-Stone, C., Kwok, J., Hodges, J., Kiernan, M., Halliday, G., Hornberger, M. (2014). Cerebellar Integrity in the Amyotrophic Lateral Sclerosis - Frontotemporal Dementia Continuum. PloS One, 9(8), e105632. [More Information]
  • Davies, K., Bohic, S., Carmona, A., Ortega, R., Cottam, V., Hare, D., Finberg, J., Reyes, S., Halliday, G., Mercer, J., Double, K. (2014). Copper pathology in vulnerable brain regions in Parkinson's disease. Neurobiology of Aging, 35(4), 858-866. [More Information]
  • Stoessl, A., Halliday, G. (2014). DAT-SPECT diagnoses dopamine depletion, but not PD. Movement Disorders, 29(14), 1705-1706. [More Information]
  • Blennerhassett, R., Lillo, P., Halliday, G., Hodges, J., Kril, J. (2014). Distribution of Pathology in Frontal Variant Alzheimer's Disease. Journal of Alzheimer's Disease, 39(1), 63-70. [More Information]
  • Coupland, K., Mellick, G., Silburn, P., Mather, K., Armstrong, N., Sachdev, P., Brodaty, H., Huang, Y., Halliday, G., Hallupp, M., et al (2014). DNA methylation of the MAPT gene in Parkinson's disease cohorts and modulation by vitamin E in vitro. Movement Disorders, 29(13), 1606-1614. [More Information]
  • Wong, J., Halliday, G., Kim, W. (2014). Exploring myelin dysfunction in multiple system atrophy. Experimental Neurobiology, 23(4), 337-344. [More Information]
  • Ferrari, R., Hernandez, D., Nalls, M., Rohrer, J., Ramasamy, A., Kwok, J., Dobson-Stone, C., Brooks, W., Schofield, P., Halliday, G., et al (2014). Frontotemporal dementia and its subtypes: A genome-wide association study. The Lancet Neurology, 13(7), 686-699. [More Information]
  • Bras, J., Guerreiro, R., Darwent, L., Ansorge, O., Escott-Price, V., Hernandez, D., Nalls, M., Clark, L., Honig, L., Halliday, G., et al (2014). Genetic analysis implicates APOE, SNCA and suggests lysosomal dysfunction in the etiology of dementia with Lewy bodies. Human Molecular Genetics, 23(23), 6139-6146. [More Information]
  • Murphy, K., Halliday, G. (2014). Glucocerebrosidase deficits in sporadic Parkinson disease. Autophagy, 10(7), 1350-1351. [More Information]
  • Po, K., Leslie, F., Gracia, N., Bartley, L., Kwok, J., Halliday, G., Hodges, J., Burrell, J. (2014). Heritability in frontotemporal dementia: more missing pieces? Journal of Neurology, 261(11), 2170-2177. [More Information]
  • Hall, H., Reyes, S., Landeck, N., Bye, C., Leanza, G., Double, K., Thompson, L., Halliday, G., Kirik, D. (2014). Hippocampal Lewy pathology and cholinergic dysfunction are associated with dementia in Parkinson's disease. Brain, 137(9), 2493-2508. [More Information]
  • Howitt, J., Gysbers, A., Ayton, S., Carew-Jones, F., Putz, U., Finkelstein, D., Halliday, G., Tan, S. (2014). Increased Ndfip1 in the substantia nigra of parkinsonian brains is associated with elevated iron levels. PloS One, 9(1), 1-7. [More Information]
  • Bleasel, J., Wong, J., Halliday, G., Kim, W. (2014). Lipid dysfunction and pathogenesis of multiple system atrophy. Acta Neuropathologica Communications, 2, 1-11. [More Information]
  • Lam, B., Halliday, G., Irish, M., Hodges, J., Piguet, O. (2014). Longitudinal white matter changes in frontotemporal dementia subtypes. Human Brain Mapping, 35(7), 3547-3557. [More Information]
  • Kordower, J., Halliday, G. (2014). Misfolded proteins in Huntington disease fetal grafts: further evidence of cell-to-cell transfer? Annals of Neurology, 76(1), 20-21. [More Information]
  • Chare, L., Hodges, J., Leyton, C., McGinley, C., Tan, R., Kril, J., Halliday, G. (2014). New criteria for frontotemporal dementia syndromes: clinical and pathological diagnostic implications. Journal of Neurology, Neurosurgery and Psychiatry, 85(8), 865-870.
  • Chare, L., Hodges, J., Leyton, C., McGinley, C., Tan, R., Kril, J., Halliday, G. (2014). New criteria for frontotemporal dementia syndromes: clinical and pathological diagnostic implications. Journal of Neurology, Neurosurgery and Psychiatry, 85(8), 866-871. [More Information]
  • Dzamko, N., Zhou, J., Huang, Y., Halliday, G. (2014). Parkinson's disease-implicated kinases in the brain; insights into disease pathogenesis. Frontiers in Molecular Neuroscience, 7, 1-15. [More Information]
  • Kragh, C., Gysbers, A., Rockenstein, E., Murphy, K., Halliday, G., Masliah, E., Jensen, P. (2014). Prodegenerative IkBa expression in oligodendroglial a-synuclein models of multiple system atrophy. Neurobiology of Disease, 63, 171-183. [More Information]
  • Murphy, K., Gysbers, A., Abbott, S., Tayebi, N., Kim, W., Sidransky, E., Cooper, A., Garner, B., Halliday, G. (2014). Reduced glucocerebrosidase is associated with increased alpha-synuclein in sporadic Parkinson's disease. Brain, 137(3), 834-848. [More Information]
  • Ahmed, R., MacMillan, M., Bartley, L., Halliday, G., Kiernan, M., Hodges, J., Piguet, O. (2014). Systemic metabolism in frontotemporal dementia. Neurology, 83, 1812-1818. [More Information]
  • Riley, B., Gardai, S., Emig-Agius, D., Bessarabova, M., Ivliev, A., Schule, B., Alexander, J., Wallace, W., Halliday, G., et al (2014). Systems-based analyses of brain regions functionally impacted in Parkinson's disease reveals underlying causal mechanisms. PloS One, 9(8), 1-14. [More Information]
  • Halliday, G., Leverenz, J., Schneider, J., Adler, C. (2014). The neurobiological basis of cognitive impairment in Parkinson's disease. Movement Disorders, 29(5), 634-650. [More Information]
  • Shine, J., Halliday, G., Gilat, M., Matar, E., Bolitho, S., Carlos, M., Naismith, S., Lewis, S. (2014). The role of dysfunctional attentional control networks in visual misperceptions in Parkinson's disease. Human Brain Mapping, 35(5), 2206-2219. [More Information]
  • Berg, D., Postuma, R., Bloem, B., Dubois, B., Gasser, T., Goetz, C., Halliday, G., Hardy, J., Lang, A., Litvan, I., et al (2014). Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson's disease. Movement Disorders, 29(4), 454-462. [More Information]
  • Gallagher, M., Suh, E., Grossman, M., Elman, L., McCluskey, L., van Swieten, J., Al‑Sarraj, S., Neumann, M., Halliday, G., Kril, J., et al (2014). TMEM106B is a genetic modifier of frontotemporal lobar degeneration with C9orf72 hexanucleotide repeat expansions. Acta Neuropathologica, 127(3), 407-418. [More Information]
  • Shine, J., O'Callaghan, C., Halliday, G., Lewis, S. (2014). Tricks of the mind: Visual hallucinations as disorders of attention. Progress in Neurobiology, 116, 58-65. [More Information]
  • Muller, A., Shine, J., Halliday, G., Lewis, S. (2014). Visual hallucinations in Parkinson's disease: Theoretical models. Movement Disorders, 29(13), 1591-1598. [More Information]
  • Nalls, M., Duran, R., Lopez, G., Kurzawa-Akanbi, M., McKeith, I., Chinnery, P., Morris, C., Theuns, J., Crosiers, D., Cras, P., et al (2013). A multicenter study of glucocerebrosidase mutations in dementia with Lewy bodies. JAMA Neurology, 70(6), 727-735. [More Information]
  • Kim, W., Hsiao, J., Bhatia, S., Glaros, E., Don, A., Tsuruoka, S., Weickert, C., Halliday, G. (2013). ABCA8 stimulates sphingomyelin production in oligodendrocytes. Biochemical Journal, 452(3), 401-410. [More Information]
  • Abbott, S., Jenner, A., Mitchell, T., Brown, S., Halliday, G., Garner, B. (2013). An improved high-throughput lipid extraction method for the analysis of human brain lipids. Lipids, 48(3), 307-318. [More Information]
  • Murphy, K., Cottle, L., Gysbers, A., Cooper, A., Halliday, G. (2013). ATP13A2 (PARK9) protein levels are reduced in brain tissue of cases with Lewy bodies. Acta Neuropathologica Communications, 1(1), 1-8. [More Information]
  • Huang, Y., Halliday, G. (2013). Can we clinically diagnose dementia with Lewy bodies yet? Translational Neurodegeneration, 2(1), 1-9. [More Information]
  • Tan, R., Shepherd, C., Kril, J., McCann, H., McGeachie, A., McGinley, C., Affleck, A., Halliday, G. (2013). Classification of FTLD-TDP cases into pathological subtypes using antibodies against phosphorylated and non-phosphorylated TDP43. Acta Neuropathologica Communications, 1(1), 1-9. [More Information]
  • Kemp, S., Harding, A., Halliday, G., Mahant, N., Fung, V. (2013). Cortical limb myoclonus in pathologically proven progressive supranuclear palsy. Movement Disorders, 28(13), 1804-1806. [More Information]
  • Kordower, J., Olanow, C., Dodiya, H., Chu, Y., Beach, T., Adler, C., Halliday, G., Bartus, R. (2013). Disease duration and the integrity of the nigrostriatal system in Parkinson's disease. Brain, 136(8), 2419-2431. [More Information]
  • Wang, J., Gouda-Vossos, A., Dzamko, N., Halliday, G., Huang, Y. (2013). DNA extraction from fresh-frozen and formalin-fixed, paraffinembedded human brain tissue. Neuroscience Bulletin, 29(5), 649-654. [More Information]
  • Hsiao, J., Fu, Y., Hill, A., Halliday, G., Kim, W. (2013). Elevation in Sphingomyelin Synthase Activity Is Associated with Increases in Amyloid-Beta Peptide Generation. PloS One, 8(8). [More Information]
  • Dang, T., Dobson-Stone, C., Glaros, E., Kim, W., Hallupp, M., Bartley, L., Piguet, O., Hodges, J., Halliday, G., Double, K., et al (2013). Endogenous progesterone levels and frontotemporal dementia: Modulation of TDP-43 and Tau levels in vitro and treatment of the A315T TARDBP mouse model. Disease Models and Mechanisms, 6(5), 1198-1204. [More Information]
  • Kragh, C., Fillon, G., Gysbers, A., Hansen, H., Neumann, M., Richter-Landsberg, C., Zalc, B., Lubetzki, C., Gai, W., Halliday, G., et al (2013). FAS-Dependent Cell Death in ?-Synuclein Transgenic Oligodendrocyte Models of Multiple System Atrophy. PloS One, 8(1), 1-9. [More Information]
  • Dobson-Stone, C., Thompson, E., Luty, A., Blumbergs, P., Brooks, W., Short, C., Field, C., Panegyres, P., Hecker, J., Halliday, G., et al (2013). Frontotemporal dementia-amyotrophic lateral sclerosis syndrome locus on chromosome 16p12.1-q12.2: Genetic, clinical and neuropathological analysis. Acta Neuropathologica, 125(4), 523-533. [More Information]
  • Bleasel, J., Hsiao, J., Halliday, G., Kim, W. (2013). Increased expression of ABCA8 in multiple system atrophy brain is associated with changes in pathogenic proteins. Journal of Parkinson's Disease, 3(3), 331-339. [More Information]
  • Cheshire, P., Bertram, K., Ling, H., O'Sullivan, S., Halliday, G., McLean, C., Bras, J., Foltynie, T., Storey, E., Williams, D. (2013). Influence of single nucleotide polymorphisms in COMT, MAO-A and BDNF genes on dyskinesias and levodopa use in Parkinson's disease. Neurodegenerative Diseases, 13(1), 24-28. [More Information]
  • Davies, K., Hare, D., Cottam, V., Chen, N., Hilgers, L., Halliday, G., Mercer, J., Double, K. (2013). Localization of copper and copper transporters in the human brain. Metallomics, 5(1), 43-51. [More Information]
  • Guerreiro, P., Huang, Y., Gysbers, A., Cheng, D., Gai, W., Outeiro, T., Halliday, G. (2013). LRRK2 interactions with ?-synuclein in Parkinson's disease brains and in cell models. Journal of Molecular Medicine, 91(4), 513-522. [More Information]
  • Dzamko, N., Chua, G., Ranola, M., Rowe, D., Halliday, G. (2013). Measurement of LRRK2 and Ser910/935 phosphorylated LRRK2 in peripheral blood mononuclear cells from idiopathic Parkinson's disease patients. Journal of Parkinson's Disease, 3(2), 145-152. [More Information]
  • Halliday, G. (2013). Motor deficits associated with changes in β-amyloid in Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry, 84(5), 475-476. [More Information]
  • Ravenscroft, T., Baker, M., Rutherford, N., Neumann, M., Mackenzie, I., Josephs, K., Boeve, B., Petersen, R., Halliday, G., Kril, J., et al (2013). Mutations in protein N-arginine methyltransferases are not the cause of FTLD-FUS. Neurobiology of Aging, 34(9), 2235.e11-2235.e13. [More Information]
  • Kavanagh, T., Mills, J., Kim, W., Halliday, G., Janitz, M. (2013). Pathway analysis of the human brain transcriptome in disease. Journal of Molecular Neuroscience, 51(1), 28-36. [More Information]
  • Tan, R., Wong, S., Hodges, J., Halliday, G., Hornberger, M. (2013). Retrosplenial cortex (BA 29) volumes in behavioral variant frontotemporal dementia and alzheimer's disease. Dementia and Geriatric Cognitive Disorders, 35(3-4), 177-182. [More Information]
  • Zhou, J., Zhang, H., Huang, Y., He, Y., Anderson, J., Gai, W., Liang, Z., Wang, Y., Ren, X., Halliday, G., et al (2013). Tenuigenin attenuates alpha-synuclein-induced cytotoxicity by down-regulating polo-like kinase 3. CNS Neuroscience and Therapeutics, 19(9), 688-694. [More Information]
  • Tan, R., Pok, K., Wong, S., Brooks, D., Halliday, G., Kril, J. (2013). The pathogenesis of cingulate atrophy in behavioral variant frontotemporal dementia and Alzheimer's disease. Acta Neuropathologica Communications, 1(30), 1-6. [More Information]
  • Reyes, S., Fu, Y., Double, K., Cottam, V., Thompson, L., Kirik, D., Paxinos, G., Watson, C., Cooper, H., Halliday, G. (2013). Trophic factors differentiate dopamine neurons vulnerable to Parkinson's disease. Neurobiology of Aging, 34(3), 873-886. [More Information]
  • Mills, J., Kavanagh, T., Kim, W., Chen, B., Kawahara, Y., Halliday, G., Janitz, M. (2013). Unique Transcriptome Patterns of the White and Grey Matter Corroborate Structural and Functional Heterogeneity in the Human Frontal Lobe. PloS One, 8(10), 1-18. [More Information]
  • Dzamko, N., Halliday, G. (2013). Unlocking the secrets of LRRK2 function with selective kinase inhibitors. Future Neurology, 8(3), 347-357. [More Information]
  • Fu, Y., Yuan, Y., Halliday, G., Rusznak, Z., Watson, C., Paxinos, G. (2012). A cytoarchitectonic and chemoarchitectonic analysis of the dopamine cell groups in the substantia nigra, ventral tegmental area, and retrorubral field in the mouse. Brain Structure and Function, 217(2), 591-612. [More Information]
  • Wong, J., Higgins, M., Halliday, G., Garner, B. (2012). Amyloid beta selectively modulates neuronal TrkB alternative transcript expression with implications for Alzheimer's disease. Neuroscience, 210, 363-374. [More Information]
  • Dzamko, N., Halliday, G. (2012). An emerging role for LRRK2 in the immune system. Biochemical Society Transactions, 40(5), 1134-1139. [More Information]
  • Halliday, G. (2012). An evidence base for noradrenergic deficits in Parkinson's disease. Movement Disorders, 27(13), 1589-1591. [More Information]
  • Lewis, S., Shine, J., Duffy, S., Halliday, G., Naismith, S. (2012). Anterior Cingulate Integrity: Executive and Neuropsychiatric Features in Parkinson's Disease. Movement Disorders, 27(10), 1262-1267. [More Information]
  • Huang, Y., Halliday, G. (2012). Aspects of innate immunity and Parkinson's disease. Frontiers in Pharmacology, 3, 1-10. [More Information]
  • Dobson-Stone, C., Hallupp, M., Bartley, L., Shepherd, C., Halliday, G., Schofield, P., Hodges, J., Kwok, J. (2012). C9ORF72 repeat expansion in clinical and neuropathologic frontotemporal dementia cohorts. Neurology, 79(10), 995-1001. [More Information]
  • Kim, W., Halliday, G. (2012). Changes in sphingomyelin level affect alpha-synuclein and ABCA5 expression. Journal of Parkinson's Disease, 2(1), 41-46. [More Information]
  • Halliday, G., McCann, H., Shepherd, C. (2012). Evaluation of the Braak hypothesis: How far can it explain the pathogenesis of Parkinson's disease? Expert Review of Neurotherapeutics, 12(6), 673-686. [More Information]
  • Reyes, S., Fu, Y., Double, K., Thompson, L., Kirik, D., Paxinos, G., Halliday, G. (2012). GIRK2 expression in dopamine neurons of the substantia nigra and ventral tegmental area. The Journal of Comparative Neurology, 520(12), 2591-2607. [More Information]
  • Hornberger, M., Wong, S., Tan, R., Irish, M., Piguet, O., Kril, J., Hodges, J., Halliday, G. (2012). In vivo and post-mortem memory circuit integrity in frontotemporal dementia and Alzheimer's disease. Brain, 135(10), 3015-3025. [More Information]
  • Shine, J., Halliday, G., Carlos, M., Naismith, S., Lewis, S. (2012). Investigating Visual Misperceptions in Parkinson's Disease: A Novel Behavioral Paradigm. Movement Disorders, 27(4), 500-505. [More Information]
  • Sharpe, L., Wong, J., Garner, B., Halliday, G., Brown, A. (2012). Is seladin-1 really a selective alzheimer's disease indicator? Journal of Alzheimer's Disease, 30(1), 35-39. [More Information]
  • Elliott, D., Kim, W., Gorrisen, S., Halliday, G., Kwok, J. (2012). Leucine-rich repeat kinase 2 and alternative splicing in Parkinson's disease. Movement Disorders, 27(8), 1004-1011. [More Information]
  • Huang, Y., Chegini, F., Chua, G., Murphy, K., Gai, W., Halliday, G. (2012). Macroautophagy in sporadic and the genetic form of Parkinson's disease with the A53T ?-synuclein mutation. Translational Neurodegeneration, 1, 1-7. [More Information]
  • Halliday, G., Bigio, E., Cairns, N., Neumann, M., Mackenzie, I., Mann, D. (2012). Mechanisms of disease in frontotemporal lobar degeneration: Gain of function versus loss of function effects. Acta Neuropathologica, 124(3), 373-382. [More Information]
  • Valenzuela, M., Matthews, F., Brayne, C., Ince, P., Halliday, G., Kril, J., Dalton, M., Richardson, K., Forster, G., Sachdev, P. (2012). Multiple Biological Pathways Link Cognitive Lifestyle to Protection from Dementia. Biological Psychiatry, 71(9), 783-791. [More Information]
  • Stevens, C., Rowe, D., Morel-Kopp, M., Orr, C., Russell, T., Ranola, M., Ward, C., Halliday, G. (2012). Reduced T helper and B lymphocytes in Parkinson's disease. Journal of Neuroimmunology, 252(1-2), 95-99. [More Information]
  • Lim, Y., Giese, M., Shepherd, C., Halliday, G., Kobayashi, M., Takamatsu, K., Staufenbiel, M., Eckert, A., Goetz, J. (2012). Role of hippocalcin in mediating AB toxicity. Biochimica et Biophysica Acta. Molecular and Cell Biology of Lipids, 1822 (8), 1247-1257. [More Information]
  • Schwartz, R., Halliday, G., Cordato, D., Kril, J. (2012). Small-Vessel Disease in Patients with Parkinson's Disease: A Clinicopathological Study. Movement Disorders, 27(12), 1506-1512. [More Information]
  • Wong, J., Garner, B., Halliday, G., Kwok, J. (2012). Srp20 regulates TrkB pre-mRNA splicing to generate TrkB-Shc transcripts with implications for Alzheimer's disease. Journal of Neurochemistry, 123(1), 159-171. [More Information]
  • Schofield, E., Hodges, J., Bak, T., Xuereb, J., Halliday, G. (2012). The relationship between clinical and pathological variables in Richardson's syndrome. Journal of Neurology, 259(3), 482-490. [More Information]
  • Zhou, J., Broe, M., Huang, Y., Anderson, J., Gai, W., Milward, E., Porritt, M., Howells, D., Hughes, A., Wang, X., et al (2011). Changes in the solubility and phosphorylation of alpha-synuclein over the course of Parkinson's disease. Acta Neuropathologica, 121(6), 695-704. [More Information]
  • Song, Y., Huang, Y., Halliday, G. (2011). Clinical correlates of similar pathologies in parkinsonian syndromes. Movement Disorders, 26(3), 499-506. [More Information]
  • Piguet, O., Halliday, G., Reid, W., Casey, B., Carman, R., Huang, Y., Xuereb, J., Hodges, J., Kril, J. (2011). Clinical phenotypes in autopsy-confirmed Pick disease. Neurology, 76(3), 253-259. [More Information]
  • Sachdev, P., Lee, T., Lammel, A., Crawford, J., Trollor, J., Wright, M., Brodaty, H., Ames, D., Halliday, G., et al (2011). Cognitive functioning in older twins: The Older Australian Twins Study. Australasian Journal on Ageing, 30(SUPPL 2), 17-23. [More Information]
  • Schofield, E., Hodges, J., Macdonald, V., Cordato, N., Kril, J., Halliday, G. (2011). Cortical Atrophy Differentiates Richardson's Syndrome from the Parkinsonian Form of Progressive Supranuclear Palsy. Movement Disorders, 26(2), 256-263. [More Information]
  • Reid, W., Hely, M., Morris, J., Loy, C., Halliday, G. (2011). Dementia in Parkinson's disease: a 20-year neuropsychological study (Sydney Multicentre Study). Journal of Neurology, Neurosurgery and Psychiatry, 82(9), 1033-1037. [More Information]
  • Piguet, O., Petersen, A., Lam, B., Gabery, S., Murphy, K., Hodges, J., Halliday, G. (2011). Eating and hypothalamus changes in behavioral-variant frontotemporal dementia. Annals of Neurology, 69(2), 312-319. [More Information]
  • Huang, Y., Zheng, L., Halliday, G., Dobson-Stone, C., Wang, Y., Tang, H., Cao, L., Deng, Y., Wang, G., Zhang, Y., et al (2011). Genetic polymorphisms in sigma-1 receptor and apolipoprotein E interact to influence the severity of alzheimer's disease. Current Alzheimer Research, 8(7), 765-770. [More Information]
  • Halliday, G., Stevens, C. (2011). Glia: Initiators and progressors of pathology in Parkinson's disease. Movement Disorders, 26(1), 6-17. [More Information]
  • Huang, Y., Rowe, D., Halliday, G. (2011). Interaction between a-synuclein and tau genotypes and the progression of Parkinson's disease. Journal of Parkinson's Disease, 1(3), 271-276. [More Information]
  • Elliott, D., Tsoi, K., Holinkova, S., Chan, S., Kim, W., Halliday, G., Rye, K., Garner, B. (2011). Isoform-specific proteolysis of apolipoprotein-E in the brain. Neurobiology of Aging, 32(2), 257-271. [More Information]
  • Cheng, D., Jenner, A., Shui, G., Cheong, W., Mitchell, T., Nealon, J., Kim, W., McCann, H., Wenk, M., Halliday, G., et al (2011). Lipid pathway alterations in parkinson's disease primary visual cortex. PloS One, 6(2), 1-17. [More Information]
  • Halliday, G., Lees, A., Stern, M. (2011). Milestones in Parkinson's disease-Clinical and pathologic features. Movement Disorders, 26(6), 1015-1021. [More Information]
  • Halliday, G., Holton, J., Revesz, T., Dickson, D. (2011). Neuropathology underlying clinical variability in patients with synucleinopathies. Acta Neuropathologica, 122(2), 187-204. [More Information]
  • Masters, C., Kril, J., Halliday, G., Pamphlett, R., Collins, S., Hill, A., McLean, C. (2011). Overview and recent advances in neuropathology. Part 2: Neurodegeneration. Journal of Pathology, 43(2), 93-102. [More Information]
  • Kril, J., Halliday, G. (2011). Pathological Staging of Frontotemporal Lobar Degeneration. Journal of Molecular Neuroscience, 45(3), 379-383. [More Information]
  • Halliday, G., Song, C., Harding, A. (2011). Striatal β-amyloid in dementia with Lewy bodies but not Parkinson's disease. Journal of Neural Transmission, 118(5), 713-719. [More Information]
  • Komadina, N., Terpening, Z., Huang, Y., Halliday, G., Naismith, S., Lewis, S. (2011). Utility and Limitations of Addenbrooke's Cognitive Examination-Revised for Detecting Mild Cognitive Impairment in Parkinson's Disease. Dementia and Geriatric Cognitive Disorders, 31(5), 349-357. [More Information]
  • Shine, J., Halliday, G., Naismith, S., Lewis, S. (2011). Visual misperceptions and hallucinations in Parkinson's disease: Dysfunction of attentional control networks? Movement Disorders, 26(12), 2154-2159. [More Information]
  • Gabery, S., Murphy, K., Schultz, K., Loy, C., McCusker, E., Kirik, D., Halliday, G., Petersen, A. (2010). Changes in Key Hypothalamic Neuropeptide Populations in Huntington Disease Revealed by Neuropathological Analyses. Acta Neophilologica, 120, 777-788. [More Information]
  • Werry, E., Enjeti, S., Halliday, G., Sachdev, P., Double, K. (2010). Effect of age on proliferation-regulating factors in human adult neurogenic areas. Journal of Neurochemistry, 115(4), 956-964. [More Information]
  • Schofield, E., Halliday, G., Kwok, J., Loy, C., Double, K., Hodges, J. (2010). Low Serum Progranulin Predicts the Presence of Mutations: A Prospective Study. Journal of Alzheimer's Disease, 22(3), 981-984. [More Information]
  • Mackenzie, I., Neumann, M., Bigio, E., Cairns, N., Alafuzoff, I., Kril, J., Kovacs, G., Ghetti, B., Halliday, G., Holm, I., et al (2010). Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an update. Acta Neuropathologica, 119(1), 1-4. [More Information]
  • Luty, A., Kwok, J., Dobson-Stone, C., Loy, C., Coupland, K., Karlstrom, H., Sobow, T., Tchorzewska, J., Maruszak, A., Barcikowsk, M., Blair, I., et al (2010). Sigma Nonopioid Intracellular Receptor 1 Mutations Cause Frontotemporal Lobar Degeneration-Motor Neuron Disease. Annals of Neurology, 68(5), 639-649. [More Information]
  • Loy, C., Kril, J., Trollor, J., Kiernan, M., Kwok, J., Vucic, S., Halliday, G., Hodges, J. (2010). The case of a 48 year-old woman with bizarre and complex delusions. Nature Reviews Neurology, 6(3), 175-179. [More Information]
  • Double, K., Rowe, D., Carew-Jones, F., Hayes, M., Chan, D., Blackie, J., Corbett, A., Joffe, R., Fung, V., Morris, J., et al (2009). Anti-melanin antibodies are increased in sera in Parkinson's disease. Experimental Neurology, 217, 297-301. [More Information]
  • Piguet, O., Halliday, G., Creasey, H., Broe, G., Kril, J. (2009). Frontotemporal dementia and dementia with Lewy bodies in a case-control study of Alzheimer's disease. International Psychogeriatrics, 21(4), 688-695. [More Information]
  • Mehta, P., Mellick, G., Rowe, D., Halliday, G., Jones, M., Manwaring, N., Vandebona, H., Silburn, P., Wang, J., Mitchell, P., Sue, C. (2009). Mitochondrial DNA Haplogroups J and K are not Protective for Parkinson's Disease in the Australian Community. Movement Disorders, 24(2), 290-292. [More Information]
  • Monoranu, C., Apfelbacher, M., Grunblatt, E., Puppe, B., Alafuzoff, I., Ferrer, I., Al-Saraj, S., Keyvani, K., Schmitt, A., Falkai, P., Kril, J., Harper, C., et al (2009). pH measurement as quality control on human post mortem brain tissue: a study of the BrainNet Europe consortium. Neuropathology and Applied Neurobiology, 35(3), 329-337. [More Information]
  • Van Eersel, J., Bi, M., Ke, Y., Hodges, J., Xuereb, J., Gregory, G., Halliday, G., Goetz, J., Kril, J., Ittner, L. (2009). Phosphorylation of soluble tau differs in Pick's disease and Alzheimer's disease brains. Journal of Neural Transmission, 116(10), 1243-1251. [More Information]
  • Truong, L., Brooks, D., Amaral, F., Henderson, J., Halliday, G. (2009). Relative preservation of thalamic centromedian nucleus in parkinsonian patients with dystonia. Movement Disorders, 24(14), 2128-2135. [More Information]
  • Kril, J., Davis, R., Halliday, G., Xuereb, J., Hodges, J. (2009). The neural basis of semantic memory: Evidence from semantic dementia. Neurobiology of Aging, 30(12), 2043-2052. [More Information]
  • Piguet, O., Double, K., Kril, J., Harasty, J., Macdonald, V., McRitchie, D., Halliday, G. (2009). White matter loss in healthy ageing: A postmortem analysis. Neurobiology of Aging, 30(8), 1288-1295. [More Information]
  • Sutherland, G., Mellick, G., Newman, J., Double, K., Stevens, J., Lee, L., Rowe, D., Silburn, P., Halliday, G. (2008). Haplotype analysis of the IGF2-INS-TH gene cluster in Parkinson's disease. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 147B (4), 495-499. [More Information]
  • Young, V., Halliday, G., Kril, J. (2008). Neuropathologic correlates of white matter hyperintensities. Neurology, 71(11), 804-811. [More Information]
  • Luty, A., Kwok, J., Thompson, E., Blumbergs, P., Brooks, W., Loy, C., Dobson-Stone, C., Panegyres, P., Hecker, J., Nicholson, G., et al (2008). Pedigree with frontotemporal lobar degeneration--motor neuron disease and Tar DNA binding protein-43 positive neuropathology: genetic linkage to chromosome 9. BMC Neurology, 8(32), 1-11. [More Information]
  • Double, K., Dedov, V., Fedorow, H., Kettle, E., Halliday, G., Garner, B., Brunk, U. (2008). The comparative biology of neuromelanin and lipofuscin in the human brain. Cellular and Molecular Life Sciences, 65, 1669-1682. [More Information]
  • Halliday, G., Hely, M., Reid, W., Morris, J. (2008). The progression of pathology in longitudinally followed patients with Parkinson's disease. Acta Neuropathologica, 115(4), 409-415. [More Information]
  • Hely, M., Reid, W., Adena, M., Halliday, G., Morris, J. (2008). The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years. Movement Disorders, 23(6), 837-844. [More Information]
  • Karlstrom, H., Brooks, W., Kwok, J., Broe, G., Kril, J., McCann, H., Halliday, G., Schofield, P. (2008). Variable phenotype of Alzheimer's disease with spastic paraparesis. Journal of Neurochemistry, 104(3), 573-583. [More Information]
  • Sutherland, G., Mellick, G., Sue, C., Chan, D., Rowe, D., Silburn, P., Halliday, G. (2007). A functional polymorphism in the parkin gene promoter affects the age of onset of Parkinson's disease. Neuroscience Letters, 414(2), 170-173. [More Information]
  • Kipps, C., Davies, R., Mitchell, J., Kril, J., Halliday, G., Hodges, J. (2007). Clinical significance of lobar atrophy in frontotemporal dementia: application of an MRI visual rating scale. Dementia and Geriatric Cognitive Disorders, 23(5), 334-342. [More Information]
  • Kipps, C., Davies, R., Mitchell, J., Kril, J., Halliday, G., Hodges, J. (2007). Clinical significance of lobar atrophy in frontotemporal dementia: Application of an MRI visual rating scale. Dementia and Geriatric Cognitive Disorders, 23(5), 334-342. [More Information]
  • Gupta, R., Dixon, K., Deo, S., Holliday, C., Slater, M., Halliday, G., Reeve, V., Mason, R. (2007). Photoprotection by 1,25 Dihydroxyvitamin D3 Is Associated with an Increase in p53 and a Decrease in Nitric Oxide Products. Journal of Investigative Dermatology, 127(3), 707-715. [More Information]
  • Huang, Y., Halliday, G., Vandebona, H., Mellick, G., Mastaglia, F., Stevens, J., Kwok, J., Garlepp, M., Silburn, P., Horne, M., Rowe, D., Sue, C., et al (2007). Prevalence and clinical features of common LRRK2 mutations in Australians with Parkinson's disease. Movement Disorders, 22(7), 982-989. [More Information]
  • Sutherland, G., Nowak, G., Halliday, G., Kril, J. (2007). Tau isoform expression in frontotemporal dementia without tau deposition. Journal of Clinical Neuroscience, 14(12), 1182-1185. [More Information]
  • Qi, B., Huang, Y., Rowe, D., Halliday, G. (2007). VISA - A pass to innate immunity. The International Journal of Biochemistry and Cell Biology, 39, 287-291. [More Information]
  • Piguet, O., Double, K., Kril, J., Harasty, J., Macdonald, V., McRitchie, D., Halliday, G. (2007). White matter loss in healthy ageing: A postmortem analysis. Neurobiology of Aging, doi:10.1016/j.neurobiolaging.2007.10.015(30 (8)), 1288-1295. [More Information]
  • Huang, Y., Hayes, M., Harding, A., Brooks, W., Fung, V., Rowe, D., Joffe, R., Crimmins, D., Hely, M., Halliday, G. (2006). Anticipation of onset age in familial Parkinson's disease without SCA gene mutations. Parkinsonism and Related Disorders, 12(5), 309-313. [More Information]
  • Huang, Y., Hayes, M., Harding, A., Brooks, W., Fung, V., Rowe, D., Joffe, R., Crimmins, D., Hely, M., Halliday, G. (2006). Anticipation of onset age in familial Parkinson’s disease without SCA gene mutations. Parkinsonism and Related Disorders, 12, 309-313. [More Information]
  • David, D., Ittner, L., Gehrig, P., Nergenau, D., Shepherd, C., Halliday, G., Goetz, J. (2006). beta-Amyloid treatment of two complementary P301L tau-expressing Alzheimer's disease models reveals similar deregulated cellular processes. Proteomics, 6(24), 6566-6577. [More Information]
  • Bennett, H., Piguet, O., Grayson, D., Creasey, H., Waite, L., Lye, T., Corbett, A., Hayes, M., Broe, G., Halliday, G. (2006). Cognitive, extrapyramidal, and magnetic resonance imaging predictors of functional impairment in nondemented older community dwellers: The Sydney Older Person Study. Journal of the American Geriatrics Society, 54(1), 3-10. [More Information]
  • Cordato, N., Halliday, G., Caine, D., Morris, J. (2006). Comparison of motor, cognitive and behavioural features in progressive supranuclear palsy and Parkinson's disease. Movement Disorders, 21(5), 632-638. [More Information]
  • Cordato, N., Halliday, G., Caine, D., Morris, J. (2006). Comparison of Motor, Cognitive, and Behavioral Features in Progressive Supranuclear Palsy and Parkinson's Disease. Movement Disorders, 21(5), 632-638.
  • Gregory, G., Macdonald, V., Schofield, P., Kril, J., Halliday, G. (2006). Differences in regional brain atrophy in genetic forms of Alzheimer's disease. Neurobiology of Aging, 27(3), 387-393. [More Information]
  • Halliday, G., Fedorow, H., Rickert, C., Gerlach, M., Riederer, P., Double, K. (2006). Evidence for specific phases in the development of human neuromelanin. Journal of Neural Transmission, 113, 721-728. [More Information]
  • Fedorow, H., Pickford, R., Kettle, E., Cartwright, M., Halliday, G., Gerlach, M., Riederer, P., Garner, B., Double, K. (2006). Investigation of the lipid component of neuromelanin. Journal of Neural Transmission, 113, 735-739. [More Information]
  • Pickering-Brown, S., Baker, M., Gass, J., Boeve, B., Loy, C., Brooks, W., Mackenzie, I., Martins, R., Kwok, J., Halliday, G., Kril, J., et al (2006). Mutations in Progranulin explain atypical phenotypes associated with variants in the MAPT. Brain, 129(11), 3124-3126. [More Information]
  • Halliday, G., Song, Y., Creasey, H., Morris, J., Brooks, W., Kril, J. (2006). Neuropathology in the S305S tau gene mutation. Brain, 129(3), 1-5. [More Information]
  • Piguet, O., Bennett, H., Waite, L., Kril, J., Broe, G., Creasey, H., Halliday, G. (2006). Preserved cognition and functional independence after a large right posterior cerebral artery infarct: longitudinal clinical and neuropathological findings. Neurocase, 12(2), 81-90. [More Information]
  • Davies, R., Kipps, C., Mitchell, J., Kril, J., Halliday, G., Hodges, J. (2006). Progression in Frontotemporal Dementia: Identifying a Benign Behavioral Variant by Magnetic Resonance Imaging. JAMA Neurology, 63(11), 1627-1631. [More Information]
  • Kersaitis, C., Halliday, G., Xuereb, J., Pamphlett, R., Bak, T., Hodges, J., Kril, J. (2006). Ubiquitin-positive inclusions and progression of pathology in frontotemporal dementia and motor neurone disease identifies a group with mainly early pathology. Neuropathology and Applied Neurobiology, 32(1), 83-91. [More Information]
  • Orr, C., Rowe, D., Mizuno, Y., Mori, H., Halliday, G. (2005). A possible role for humoral immunity in the pathogenesis of Parkinson's disease. Brain, 128(11), 2665-2674. [More Information]
  • Cordato, N., Duggins, A., Halliday, G., Morris, J., Pantelis, C. (2005). Clinical deficits correlate with regional cerebral atrophy in progressive supranuclear palsy. Brain, 128(6), 1259-1266. [More Information]
  • Kril, J., Macdonald, V., Patel, S., Png, F., Halliday, G. (2005). Distribution of brain atrophy in behavioral variant frontotemporal dementia. Journal of the Neurological Sciences, 232(1-2), 83-90. [More Information]
  • Fedorow, H., Pickford, R., Hook, J., Double, K., Halliday, G., Gerlach, M., Riederer, P., Garner, B. (2005). Dolichol is the major lipid component of human substantia nigra neuromelanin. Journal of Neurochemistry, 92, 990-995. [More Information]
  • Kwok, J., Hallupp, M., Loy, C., Chan, D., Woo, J., Mellick, G., Buchanan, D., Silburn, P., Halliday, G., Schofield, P. (2005). GSK3B polymorphisms alter transcription and splicing in Parkinson's disease. Annals of Neurology, 58(6), 829-839. [More Information]
  • Osborne, P., Halliday, G., Cooper, H., Keast, J. (2005). Localization of immunoreactivity for deleted in colorectal cancer (DCC), the receptor for the guidance factor netrin-1, in ventral tier dopamine projection pathways in adult rodents. Neuroscience, 131(3), 671-681. [More Information]
  • Fedorow, H., Tribl, F., Halliday, G., Gerlach, M., Riederer, P., Double, K. (2005). Neuromelanin in human dopamine neurons: Comparison with peripheral melanins and relevance to Parkinson’s disease. Progress in Neurobiology, 75, 109-124. [More Information]
  • Huang, Y., Garrick, R., Cook, R., O'Sullivan, D., Morris, J., Halliday, G. (2005). Pallidal stimulation reduces treatment-induced dyskinesias in "minimal-change" multiple system atrophy. Movement Disorders, 20(8), 1042-1047. [More Information]
  • Graham, A., Davies, R., Xuereb, J., Halliday, G., Kril, J., Creasey, H., Graham, K., Hodges, J. (2005). Pathologically proven frontotemporal dementia presenting with severe amnesia. Brain, 128(3), 597-605. [More Information]
  • Raftery, M., Campbell, R., Glaros, E., Rye, K., Halliday, G., Jessup, W., Garner, B. (2005). Phosphorylation of Apolipoprotein-E at an Atypical Protein Kinase CK2 PSD/E Site in Vitro. Biochemistry, 44(19), 7346-7353. [More Information]
  • Halliday, G., Song, Y., Lepar, G., Brooks, W., Kwok, J., Kersaitis, C., Gregory, G., Shepherd, C., Rahimi, F., Schofield, P., Kril, J. (2005). Pick bodies in a family with presenilin-1 Alzheimer's disease. Annals of Neurology, 57(1), 139-143. [More Information]
  • Schofield, E., Caine, D., Kril, J., Cordato, N., Halliday, G. (2005). Staging Disease Severity in Movement Disorder Tauopathies: Brain Atrophy Separates Progressive Supranuclear Palsy From Corticobasal Degeneration. Movement Disorders, 20(1), 34-39. [More Information]
  • Davies, R., Hodges, J., Kril, J., Patterson, K., Halliday, G., Xuereb, J. (2005). The pathological basis of semantic dementia. Brain, 128(Part 9), 1984-1995. [More Information]
  • Halliday, G., Ophof, A., Broe, M., Jensen, P., Kettle, E., Fedorow, H., Cartwright, M., Griffiths, F., Shepherd, C., Double, K. (2005). α-Synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease. Brain, 128, 2654-2664. [More Information]
  • Broe, M., Kril, J., Halliday, G. (2004). Astrocytic Degeneration Relates To The Severity Of Disease In Frontotemporal Dementia. Brain, 127(10), 2214-2220. [More Information]
  • Hodges, J., Davies, R., Xuereb, J., Casey, B., Broe, M., Bak, T., Kril, J., Halliday, G. (2004). Clinicopathological Correlates In Frontotemporal Dementia. Annals of Neurology, 56(3), 399-406. [More Information]
  • Kril, J., Halliday, G. (2004). Clinicopathological Staging Of Frontotemporal Dementia Severity: Correlation With Regional Atrophy. Dementia and Geriatric Cognitive Disorders, 17(4), 311-315. [More Information]
  • Huang, Y., Cheung, L., Rowe, D., Halliday, G. (2004). Genetic Contributions To Parkinson's Disease. Brain Research Reviews, 46(1), 44-70. [More Information]
  • Brooks, W., Kwok, J., Halliday, G., Godbolt, A., Rossor, M., Creasey, H., Jones, A., Schofield, P. (2004). Hemorrhage Is Uncommon In New Alzheimer Family With Flemish Amyloid Precursor Protein Mutation. Neurology, 63(9), 1613-1617.
  • Harding, A., Das, A., Kril, J., Brooks, W., Duffy, D., Halliday, G. (2004). Identification Of Families With Cortical Lewy Body Disease. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 128B (1), 118-122.
  • Henderson, J., Rodriguez, M., O'Sullivan, D., Pell, M., Fung, V., Benabid, A., Halliday, G. (2004). Partial Lesion Of Thalamic Ventral Intermediate Nucleus After Chronic High-Frequency Stimulation. Movement Disorders, 19(6), 709-711. [More Information]
  • Shepherd, C., Gregory, G., Vickers, J., Brooks, W., Kwok, J., Schofield, P., Kril, J., Halliday, G. (2004). Positional Effects Of Presenilin-1 Mutations On Tau Phosphorylation In Cortical Plaques. Neurobiology of Disease, 15(1), 115-119. [More Information]
  • Kersaitis, C., Halliday, G., Kril, J. (2004). Regional And Cellular Pathology In Frontotemporal Dementia: Relationship To Stage Of Disease In Cases With And Without Pick Bodies. Acta Neuropathologica, 108(6), 515-523. [More Information]
  • Kril, J., Hodges, J., Halliday, G. (2004). Relationship Between Hippocampal Volume And Ca1 Neuron Loss In Brains Of Humans With And Without Alzheimer'S Disease. Neuroscience Letters, 361(1-3), 9-12. [More Information]
  • Halliday, G., Double, K., Macdonald, V., Kril, J. (2003). Identifying severely atrophic cortical subregions in Alzheimer's disease. Neurobiology of Aging, 24(6), 797-806.
  • Double, K., Rowe, D., Hayes, M., Chan, D., Blackie, J., Corbett, A., Joffe, R., Fung, V., Morris, J., Halliday, G. (2003). Identifying the Pattern of Olfactory Deficits in Parkinson Disease Using the Brief Smell Identification Test. JAMA Neurology, 60(4), 545-549. [More Information]
  • Stanford, P., Shepherd, C., Halliday, G., Brooks, W., Schofield, P., Brodaty, H., Martins, R., Kwok, J., Schofield, P. (2003). Mutations in the tau gene that cause an increase in three repeat tau and frontotemporal dementia. Brain, 126(4), 814-826.
  • Schofield, E., Kersaitis, C., Shepherd, C., Kril, J., Halliday, G. (2003). Severity of gliosis in Pick's disease and frontotemporal lobar degeneration: tau-positive glia differentiate these disorders. Brain, 126(4), 827-840.
  • Broe, M., Hodges, J., Schofield, E., Shepherd, C., Kril, J., Halliday, G. (2003). Staging disease severity in pathologically confirmed cases of frontotemporal dementia. Neurology, 60(6), 1005-1011.
  • Harasty, J., Seldon, H., Chan, P., Halliday, G., Harding, A. (2003). The left human speech-processing cortex is thinner but longer than the right. Laterality: asymmetries of body, brain and cognition, 8(3), 247-260.
  • Halliday, G., Ng, T., Rodriguez, M., Harding, A., Blumbergs, P., Evans, W., Fabian, V., Fryer, J., Gonzales, M., Harper, C., Pamphlett, R., Kril, J., et al (2002). Consensus neuropathological diagnosis of common dementia syndromes: testing and standardising the use of multiple diagnostic criteria. Acta Neuropathologica, 104(1), 72-78. [More Information]
  • Cordato, N., Pantelis, C., Halliday, G., Velakoulis, D., Wood, S., Stuart, G., Currie, J., Soo, M., Olivieri, G., Broe, G., Morris, J. (2002). Frontal atrophy correlates with behavioural changes in progressive supranuclear palsy. Brain, 125, 789-800.
  • Munch, G., Shepherd, C., McCann, H., Brooks, W., Kwok, J., Arendt, T., Hallupp, M., Schofield, P., Martins, R., Halliday, G. (2002). Intraneuronal advanced glycation endproducts in presenilin-1 Alzheimer's disease. NeuroReport, 13(5), 601-604.
  • Shepherd, C., McCann, H., Thiel, E., Halliday, G. (2002). Neurofilament-immunoreactive neurons in Alzheimer's disease and dementia with Lewy bodies. Neurobiology of Disease, 9(2), 249-257. [More Information]
  • Kril, J., Patel, S., Harding, A., Halliday, G. (2002). Neuron loss from the hippocampus of Alzheimer's disease exceeds extracellular neurofibrillary tangle formation. Acta Neuropathologica, 103(4), 370-376. [More Information]
  • Kril, J., Patel, S., Harding, A., Halliday, G. (2002). Patients with vascular dementia due to microvascular pathology have significant hippocampal neuronal loss. Journal of Neurology, Neurosurgery and Psychiatry, 72(6), 747-751. [More Information]
  • Kril, J., Halliday, G. (2001). Alzheimer's disease: its diagnosis and pathogenesis. International Review of Neurobiology, 48, 167-217.
  • Nicholson, G., Spira, P., Sharpe, J., Halliday, G., Cavanagh, J. (2001). Clinical and pathological features of a Parkinsonian syndrome in a family with an Ala53Thr alpha-synuclein mutation. Annals of Neurology, 49, 313-319.
  • Harasty, J., Croot, K., Halliday, G., Xuereb, J., Bennett, H., Hodges, J. (2001). Cortical degeneration associated with phonologic and semantic language impairments in AD. Neurology, 56, 944-950.
  • Cordato, N., Halliday, G., McCann, H., Davies, L., Williamson, P., Fulham, M., Morris, J. (2001). Corticobasal syndrome with tau pathology. Movement Disorders, 16, 656-667.
  • Caine, D., Halliday, G., Patterson, K., Hodges, J. (2001). Sever anterograde amnesia with extensive hippocampal degeneration in a case of rapidly progressive frontotemporal dementia. Neurocase, 7, 57-64.
  • Wong, D., Bishop, A., Lowes, M., Cooke, B., Barnetson, R., Halliday, G. (2000). Cytokine profiles in spontaneously regressing basal cell carcinomas. British Journal of Dermatology, 143(1), 91-98.
  • Stanford, P., Halliday, G., Brooks, W., Kwok, J., Storey, C., Creasey, H., Morris, J., Fulham, M., Schofield, P. (2000). Progresive supranuclear palsy pathology caused by a novel silent mutation in exon 10 of the tau gene: Expansion of the disease phenotype caused by tau gene mutations. Brain, 123, 880-893.

Conferences

  • Henderson, J., Halliday, G., Macdonald, V. (2005). Thalamic And Cortical Changes in Parkinsonian Disorders. The Basal Ganglia VIII, UK: Springer.

2017

  • Tan, R., Ke, Y., Ittner, L., Halliday, G. (2017). ALS/FTLD: experimental models and reality. Acta Neuropathologica, 133(2), 177-196. [More Information]
  • Kirik, D., Cederfjall, E., Halliday, G., Petersen, A. (2017). Gene therapy for Parkinson's disease: Disease modification by GDNF family of ligands. Neurobiology of Disease, 97, 179-188. [More Information]
  • Ahmed, R., Irish, M., van Eersel, J., Ittner, A., Ke, Y., Volkerling, A., van der Hoven, J., Tanaka, K., Karl, T., Kassiou, M., Kril, J., Piguet, O., Kiernan, M., Halliday, G., Hodges, J., et al (2017). Mouse models of frontotemporal dementia: A comparison of phenotypes with clinical symptomatology. Neuroscience and Biobehavioral Reviews, 74(1 March 2017), 126-138. [More Information]

2016

  • Landeck, N., Hall, H., Ardah, M., Majbour, N., El-Agnaf, O., Halliday, G., Kirik, D. (2016). A novel multiplex assay for simultaneous quantification of total and S129 phosphorylated human alpha-synuclein. Molecular Neurodegeneration, 11(1), 61. [More Information]
  • Fu, Y., Hsiao, J., Paxinos, G., Halliday, G., Kim, W. (2016). ABCA7 Mediates Phagocytic Clearance of Amyloid-beta in the Brain. Journal of Alzheimer's Disease, 54(2), 569-584. [More Information]
  • Kovacs, G., Ferrer, I., Grinberg, L., Alafuzoff, I., Attems, J., Budka, H., Cairns, N., Crary, J., Halliday, G., Kril, J., et al (2016). Aging-related tau astrogliopathy (ARTAG): harmonized evaluation strategy. Acta Neuropathologica, 131(1), 87-102. [More Information]
  • Ahmed, R., Irish, M., Piguet, O., Halliday, G., Ittner, L., Farooqi, S., Hodges, J., Kiernan, M. (2016). Amyotrophic lateral sclerosis and frontotemporal dementia: distinct and overlapping changes in eating behaviour and metabolism. The Lancet Neurology, 15(3), 332-342. [More Information]
  • Bleasel, J., Halliday, G., Kim, W. (2016). Animal modeling an oligodendrogliopathy - multiple system atrophy. Acta Neuropathologica Communications, 4(1), 1-15. [More Information]
  • O'Callaghan, C., Hornberger, M., Balsters, J., Halliday, G., Lewis, S., Shine, J. (2016). Cerebellar atrophy in Parkinson's disease and its implication for network connectivity. Brain, 139(Pt 3), 845-855. [More Information]
  • Tan, R., Kril, J., McGinley, C., Hassani, M., Masuda-Suzukake, M., Hasegawa, M., Mito, R., Kiernan, M., Halliday, G. (2016). Cerebellar neuronal loss in Amyotrophic Lateral Sclerosis cases with ATXN2 intermediate repeat expansions. Annals of Neurology, 79(2), 295-305. [More Information]
  • Chen, B., Mills, J., Takenaka, K., Bliim, N., Halliday, G., Janitz, M. (2016). Characterization of circular RNAs landscape in multiple system atrophy brain. Journal of Neurochemistry, 139(3), 485-496. [More Information]
  • Ahmed, R., Caga, J., Devenney, E., Hsieh, S., Bartley, L., Highton-Williamson, E., Ramsey, E., Zoing, M., Halliday, G., Piguet, O., Kiernan, M., et al (2016). Cognition and eating behavior in amyotrophic lateral sclerosis: effect on survival. Journal of Neurology, 263(8), 1593-1603. [More Information]
  • Weissleder, C., Fung, S., Wong, M., Barry, G., Double, K., Halliday, G., Webster, M., Weickert, C. (2016). Decline in proliferation and immature neuron markers in the human subependymal zone during aging: Relationship to EGF- and FGF-related transcripts. Frontiers in Aging Neuroscience, 8. [More Information]
  • Leyton, C., Britton, A., Hodges, J., Halliday, G., Kril, J. (2016). Distinctive pathological mechanisms involved in primary progressive aphasias. Neurobiology of Aging, 38, 82-92. [More Information]
  • Burrell, J., Forrest, S., Bak, T., Hodges, J., Halliday, G., Kril, J. (2016). Expanding the phenotypic associations of globular glial tau subtypes. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring, 4, 6-13. [More Information]
  • Schott, J., Crutch, S., Carrasquillo, M., Uphill, J., Shakespeare, T., Ryan, N., Yong, K., Lehmann, M., Ertekin-Taner, N., Halliday, G., et al (2016). Genetic risk factors for the posterior cortical atrophy variant of Alzheimer's disease. Alzheimer's and Dementia, 12(8), 862-871. [More Information]
  • Guerreiro, R., Escott-Price, V., Darwent, L., Parkkinen, L., Ansorge, O., Hernandez, D., Nalls, M., Clark, L., Honig, L., Halliday, G., et al (2016). Genome-wide analysis of genetic correlation in dementia with Lewy bodies, Parkinson's and Alzheimer's diseases. Neurobiology of Aging, 38, 214.e7-214.e10. [More Information]
  • Van der Jeugd, A., Vermaercke, B., Halliday, G., Staufenbiel, M., Gotz, J. (2016). Impulsivity, decreased social exploration, and executive dysfunction in a mouse model of frontotemporal dementia. Neurobiology of Learning and Memory, 130, 34-43. [More Information]
  • Dzamko, N., Rowe, D., Halliday, G. (2016). Increased peripheral inflammation in asymptomatic leucine-rich repeat kinase 2 mutation carriers. Movement Disorders, 31(6), 889-897. [More Information]
  • Perera, G., Ranola, M., Rowe, D., Halliday, G., Dzamko, N. (2016). Inhibitor treatment of peripheral mononuclear cells from Parkinson's disease patients further validates LRRK2 dephosphorylation as a pharmacodynamic biomarker. Scientific Reports, 6, 1-8. [More Information]
  • Matrone, C., Dzamko, N., Madsen, P., Nyegaard, M., Pohlmann, R., Sondergaard, R., Lassen, L., Andresen, T., Halliday, G., et al (2016). Mannose 6-phosphate receptor is reduced in -synuclein overexpressing models of parkinsons disease. PloS One, 11(8), 1-21. [More Information]
  • Wang, G., Huang, Y., Wang, L., Zhang, Y., Xu, J., Zhou, Y., Lourenco, G., Zhang, B., Halliday, G., et al (2016). MicroRNA-146a suppresses ROCK1 allowing hyperphosphorylation of tau in Alzheimer's disease. Scientific Reports, 6, 1-12. [More Information]
  • Shibuya, K., Park, S., Geevasinga, N., Menon, P., Howells, J., Simon, N., Huynh, W., Noto, Y., Gotz, J., Kril, J., Vucic, S., Kiernan, M., et al (2016). Motor cortical function determines prognosis in sporadic ALS. Neurology, 87(5), 513-520. [More Information]
  • Ahmed, R., Devenney, E., Irish, M., Ittner, A., Naismith, S., Ittner, L., Rohrer, J., Halliday, G., Eisen, A., Hodges, J., Kiernan, M. (2016). Neuronal network disintegration: common pathways linking neurodegenerative diseases. Journal of Neurology, Neurosurgery and Psychiatry, 87(11), 1234-1241. [More Information]
  • McCann, H., Cartwright, H., Halliday, G. (2016). Neuropathology of alpha-synuclein propagation and braak hypothesis. Movement Disorders, 31(2), 152-160. [More Information]
  • Hu, Y., Zou, Y., Huang, Y., Zhang, Y., Lourenco, G., Chen, S., Halliday, G., Wang, G., Ren, R. (2016). ROCK1 Is Associated with Alzheimer's Disease-Specific Plaques, as well as Enhances Autophagosome Formation But not Autophagic A-Beta Clearance. Frontiers in Cellular Neuroscience, 10, 1-11. [More Information]
  • Coupland, K., Kim, W., Halliday, G., Hallupp, M., Dobson-Stone, C., Kwok, J. (2016). Role of the long non-coding RNA MAPT-AS1 in regulation of microtubule associated protein tau (MAPT) expression in Parkinson's disease. PloS One, 11(6). [More Information]
  • Lobo, E., Delic (nee Roue), N., Richardson, A., Raviraj, V., Halliday, G., Di Girolamo, N., Myerscough, M., Lyons, G. (2016). Self-organized centripetal movement of corneal epithelium in the absence of external cues. Nature Communications, 7, 1-8. [More Information]
  • Mills, J., Ward, M., Kim, W., Halliday, G., Janitz, M. (2016). Strand-specific RNA-sequencing analysis of multiple system atrophy brain transcriptome. Neuroscience, 322, 234-250. [More Information]
  • Halliday, G., Kiernan, M., Kril, J., Mito, R., Masuda-Suzukake, M., Hasegawa, M., McCann, H., Bartley, L., Dobson-Stone, C., Kwok, J., et al (2016). TDP-43 in the hypoglossal nucleus identifies amyotrophic lateral sclerosis in behavioral variant frontotemporal dementia. Journal of the Neurological Sciences, 366, 197-201. [More Information]
  • Burrell, J., Halliday, G., Kril, J., Ittner, L., Gotz, J., Kiernan, M., Hodges, J. (2016). The frontotemporal dementia-motor neuron disease continuum. The Lancet, 388(10047), 919-931. [More Information]
  • Fu, Y., Paxinos, G., Watson, C., Halliday, G. (2016). The substantia nigra and ventral tegmental dopaminergic neurons from development to degeneration. Journal of Chemical Neuroanatomy, 76, 98-107. [More Information]
  • Wang, G., Huang, Y., Chen, W., Chen, S., Wang, Y., Xiao, Q., Liu, J., Fung, V., Halliday, G., Chen, S. (2016). Variants in the SNCA gene associate with motor progression while variants in the MAPT gene associate with the severity of Parkinson's disease. Parkinsonism and Related Disorders, 24, 89-94. [More Information]

2015

  • Leshchyns'ka, I., Liew, H., Shepherd, C., Halliday, G., Stevens, C., Ke, Y., Ittner, L., Sytnyk, V. (2015). A beta-dependent reduction of NCAM2-mediated synaptic adhesion contributes to synapse loss in Alzheimer's disease. Nature Communications, 6, 1-18. [More Information]
  • Fu, Y., Hsiao, J., Paxinos, G., Halliday, G., Kim, W. (2015). ABCA5 Regulates amyloid-beta peptide production and is associated with Alzheimer's disease neuropathology. Journal of Alzheimer's Disease, 43(3), 857-869. [More Information]
  • Shine, J., Muller, A., O'Callaghan, C., Hornberger, M., Halliday, G., Lewis, S. (2015). Abnormal connectivity between the default mode and the visual system underlies the manifestation of visual hallucinations in Parkinson's disease: a task-based fMRI study. NPJ Parkinson's Disease, 1, 1-8. [More Information]
  • Yang, Y., Shepherd, C., Halliday, G. (2015). Aneuploidy in Lewy body diseases. Neurobiology of Aging, 36(3), 1253-1260. [More Information]
  • Rusznak, Z., Kim, W., Hsiao, J., Halliday, G., Paxinos, G., Fu, Y. (2015). Early in vivo effects of the human mutant amyloid-? protein precursor (hA?PPSwInd) on the mouse olfactory bulb. Journal of Alzheimer's Disease, 49(2), 443-457. [More Information]
  • Ahmed, R., Latheef, S., Bartley, L., Irish, M., Halliday, G., Kiernan, M., Hodges, J., Piguet, O. (2015). Eating behavior in frontotemporal dementia. Neurology, 85(15), 1310-1317. [More Information]
  • Coupland, K., Kim, W., Halliday, G., Hallupp, M., Dobson-Stone, C., Kwok, J. (2015). Effect of PSEN1 mutations on MAPT methylation in early-onset Alzheimer�s disease. Current Alzheimer Research, 12(8), 745-751.
  • Prusiner, S., Woerman, A., Mordes, D., Watts, J., Rampersaud, R., Berry, D., Patel, S., Oehler, A., Lowe, J., Kravitz, S., et al (2015). Evidence for alpha-synuclein prions causing multiple system atrophy in humans with parkinsonism. Proceedings of the National Academy of Sciences of the United States of America (PNAS), 112(38), E5308-E5317. [More Information]
  • Abbott, S., Jenner, A., Spiro, A., Batterham, M., Halliday, G., Garner, B. (2015). Fatty acid composition of the anterior cingulate cortex indicates a high susceptibility to lipid peroxidation in Parkinson's disease. Journal of Parkinson's Disease, 5(1), 175-185. [More Information]
  • Forrest, S., Kril, J., Halliday, G. (2015). Frontotemporal lobar degeneration with tau inclusions (FTLD-tau): Recent developments in pathology and pathogenesis. Australian Biochemist, 46(1), 8-11.
  • Ittner, L., Halliday, G., Kril, J., Gotz, J., Kiernan, M. (2015). FTD and ALS-translating mouse studies into clinical trials. Nature Reviews. Neurology, 11(6), 360-366. [More Information]
  • Lewis, S., Shine, J., Brooks, D., Halliday, G. (2015). Hallucinogenic mechanisms: Pathological and pharmacological insights. In Daniel Collerton, Urs Peter Mosimann, Elaine Perry (Eds.), The Neuroscience of Visual Hallucinations, (pp. 121-149). Oxford: John Wiley & Sons. [More Information]
  • Mills, J., Kavanagh, T., Kim, W., Chen, B., Waters, P., Halliday, G., Janitz, M. (2015). High expression of long intervening non-coding RNA OLMALINC in the human cortical white matter is associated with regulation of oligodendrocyte maturation. Molecular Brain Research, 8(1), 1-12. [More Information]
  • Dzamko, N., Geczy, C., Halliday, G. (2015). Inflammation is genetically implicated in Parkinson's disease. Neuroscience, 302, 89-102. [More Information]
  • Dobson-Stone, C., Shaw, A., Hallupp, M., Bartley, L., McCann, H., Brooks, W., Loy, C., Schofield, P., Halliday, G., et al (2015). Is CHCHD10 Pro34Ser pathogenic for frontotemporal dementia and amyotrophic lateral sclerosis? Brain, 138(10), e385-e385. [More Information]
  • Mills, J., Chen, J., Kim, W., Waters, P., Prabowo, A., Aronica, E., Halliday, G., Janitz, M. (2015). Long intervening non-coding RNA 00320 is human brain-specific and highly expressed in the cortical white matter. Neurogenetics, 16(3), 201-213. [More Information]
  • Lourenco, G., Janitz, M., Huang, Y., Halliday, G. (2015). Long noncoding RNAs in TDP-43 and FUS/TLS-related frontotemporal lobar degeneration (FTLD). Neurobiology of Disease, 82, 445-454. [More Information]
  • Murphy, K., Gysbers, A., Abbott, S., Spiro, A., Furuta, A., Cooper, A., Garner, B., Kabuta, T., Halliday, G. (2015). Lysosomal-associated membrane protein 2 isoforms are differentially affected in early Parkinson's disease. Movement Disorders, 30(12), 1639-1647. [More Information]
  • Postuma, R., Berg, D., Stern, M., Poewe, W., Olanow, C., Oertel, W., Obeso, J., Marek, K., Litvan, I., Lang, A., et al (2015). MDS clinical diagnostic criteria for Parkinson's disease. Movement Disorders, 30(12), 1591-1601. [More Information]
  • Berg, D., Postuma, R., Adler, C., Bloem, B., Chan, P., Dubois, B., Gasser, T., Goetz, C., Halliday, G., et al (2015). MDS research criteria for prodromal Parkinson's disease. Movement Disorders, 30(12), 1600-1609. [More Information]
  • Cairns, N., Perrin, R., Franklin, E., Carter, D., Vincent, B., Xie, M., Bateman, R., Benzinger, T., Friedrichsen, K., Halliday, G., et al (2015). Neuropathologic assessment of participants in two multi-center longitudinal observational studies: The Alzheimer Disease Neuroimaging Initiative (ADNI) and the Dominantly Inherited Alzheimer Network (DIAN). Neuropathology, 35(4), 390-400. [More Information]
  • Duyckaerts, C., Braak, H., Brion, J., Buee, L., Del Tredici, K., Goedert, M., Halliday, G., Neumann, M., Spillantini, M., et al (2015). PART is part of Alzheimer disease. Acta Neuropathologica, 129(5), 749-756. [More Information]
  • Devenney, E., Bartley, L., Hoon, C., O'Callaghan, C., Kumfor, F., Hornberger, M., Kwok, J., Halliday, G., Kiernan, M., Piguet, O., et al (2015). Progression in Behavioral Variant Frontotemporal Dementia: A Longitudinal Study. JAMA Neurology, 72(12), 1501-1509. [More Information]
  • Halliday, G. (2015). Progressive supranuclear palsy finally has a clinically measureable Ͽ abnormality. Journal of Neurology, Neurosurgery and Psychiatry, 86(3), 241-241. [More Information]
  • Helmfors, L., Boman, A., Civitelli, L., Nath, S., Sandin, L., Janefjord, C., McCann, H., Zetterberg, H., Blennow, K., Halliday, G., et al (2015). Protective properties of lysozyme on beta-amyloid pathology: Implications for Alzheimer disease. Neurobiology of Disease, 83, 122-133. [More Information]
  • Halliday, G. (2015). Re-evaluating the glio-centric view of multiple system atrophy by highlighting the neuronal involvement. Brain, 138(Pt 8), 2116-2119. [More Information]
  • Halliday, G., Murphy, K. (2015). Reply: Lysosomal dysfunction in Parkinson's disease. Anatomy and Embryology (Brain Structure and Function), 138(4), e340. [More Information]
  • McCann, H., McGeachie, A., Silberstein, P., Lewis, S., Halliday, G. (2015). Restricted disease propagation in multiple system atrophy with prolonged survival. Neuropathology and Applied Neurobiology, 41(5), 681-685. [More Information]
  • Gabery, S., Halliday, G., Kirik, D., Englund, E., Petersen, A. (2015). Selective loss of oxytocin and vasopressin in the hypothalamus in early Huntington disease: a case study. Neuropathology and Applied Neurobiology, 41(6), 843-848. [More Information]
  • Cheshire, P., Ayton, S., Bertram, K., Ling, H., Li, A., McLean, C., Halliday, G., O'Sullivan, S., Revesz, T., Finkelstein, D., et al (2015). Serotonergic markers in Parkinson's disease and levodopa-induced dyskinesias. Movement Disorders, 30(6), 796-804. [More Information]
  • Ke, Y., Hummel, A., Stevens, C., Gladbach, A., Ippati, S., Bi, M., Lee, W., Halliday, G., Haass, N., Kiernan, M., et al (2015). Short-term suppression of A315T mutant human TDP-43 expression improves functional deficits in a novel inducible transgenic mouse model of FTLD-TDP and ALS. Acta Neuropathologica, 130(5), 661-678. [More Information]
  • Huang, Y., Wang, G., Rowe, D., Wang, Y., Kwok, J., Xiao, Q., Mastaglia, F., Liu, J., Chen, S., Halliday, G. (2015). SNCA gene, but not MAPT, influences onset age of Parkinson's Disease in Chinese and Australians. BioMed Research International, 2015, 1-6. [More Information]
  • Fatima, M., Tan, R., Halliday, G., Kril, J. (2015). Spread of pathology in amyotrophic lateral sclerosis: assessment of phosphorylated TDP-43 along axonal pathways. Acta Neuropathologica Communications, 3(1), 1-9. [More Information]
  • Tan, R., Kril, J., Fatima, M., McGeachie, A., McCann, H., Shepherd, C., Forrest, S., Affleck, A., Kwok, J., Hodges, J., Kiernan, M., et al (2015). TDP-43 proteinopathies: pathological identification of brain regions differentiating clinical phenotypes. Brain, 138(10), 3110-3122. [More Information]
  • Tan, R., Devenney, E., Kiernan, M., Halliday, G., Hodges, J., Hornberger, M. (2015). Terra incognita-cerebellar contributions to neuropsychiatric and cognitive dysfunction in behavioral variant frontotemporal dementia. Frontiers in Aging Neuroscience, 7, 1-9. [More Information]
  • Cordato, N., Halliday, G. (2015). The differentiation of progressive supranuclear palsy. Neurodegenerative Disease Management, 5(5), 385-388. [More Information]
  • Szeto, J., O’Callaghan, C., Shine, J., Walton, C., Mowszowski, L., Naismith, S., Halliday, G., Lewis, S. (2015). The relationships between mild cognitive impairment and phenotype in Parkinson’s disease. NPJ Parkinson's Disease, 1. [More Information]
  • Chen, J., Mills, J., Halliday, G., Janitz, M. (2015). The role of transcriptional control in multiple system atrophy. Neurobiology of Aging, 36(1), 394-400. [More Information]
  • Mills, J., Kim, W., Halliday, G., Janitz, M. (2015). Transcriptome analysis of grey and white matter cortical tissue in multiple system atrophy. Neurogenetics, 16(2), 107-122. [More Information]
  • McCann, H., Fung, V., Klein, C., Halliday, G. (2015). Unusual a-synuclein and cerebellar pathologies in a case of hereditary myoclonus-dystonia without SGCE mutation. Neuropathology and Applied Neurobiology, 41(6), 837-842. [More Information]
  • Shine, J., Mills, J., Qui, J., O'Callaghan, C., Terpening, Z., Halliday, G., Naismith, S., Lewis, S. (2015). Validation of the Psychosis and Hallucinations Questionnaire in Non-demented Patients with Parkinson’s Disease. Movement Disorders Clinical Practice, 2(2), 175-181. [More Information]

2014

  • McCann, H., Stevens, C., Cartwright, H., Halliday, G. (2014). a-Synucleinopathy phenotypes. Parkinsonism and Related Disorders, 20(SUPPL.1), S62-S67. [More Information]
  • Kim, W., Kagedal, K., Halliday, G. (2014). Alpha-synuclein biology in Lewy body diseases. Alzheimers Research & Therapy, 6(1), 1-9. [More Information]
  • Abbott, S., Li, H., Munoz, S., Knoch, B., Batterham, M., Murphy, K., Halliday, G., Garner, B. (2014). Altered ceramide acyl chain length and ceramide synthase gene expression in Parkinson's disease. Movement Disorders, 29(4), 518-526. [More Information]
  • Don, A., Hsiao, J., Bleasel, J., Couttas, T., Halliday, G., Kim, W. (2014). Altered lipid levels provide evidence for myelin dysfunction in multiple system atrophy. Acta Neuropathologica Communications, 2, 1-14. [More Information]
  • Tan, R., Wong, S., Kril, J., Piguet, O., Hornberger, M., Hodges, J., Halliday, G. (2014). Beyond the temporal pole: Limbic memory circuit in the semantic variant of primary progressive aphasia. Brain, 137(7), 2065-2076. [More Information]
  • Ahmed, R., Paterson, R., Warren, J., Zetterberg, H., O'Brien, J., Fox, N., Halliday, G., Schott, J. (2014). Biomarkers in dementia: Clinical utility and new directions. Journal of Neurology, Neurosurgery and Psychiatry, 85(12), 1426-1434. [More Information]
  • Mahul-Mellier, A., Fauvet, B., Gysbers, A., Dikiy, I., Oueslati, A., Georgeon, S., Lamontanara, A., Bisquertt, A., Eliezer, D., Masliah, E., et al (2014). C-Abl phosphorylates a-synuclein and regulates its degradation: Implication for a-synuclein clearance and contribution to the pathogenesis of parkinson's disease. Human Molecular Genetics, 23(11), 2858-2879. [More Information]
  • Tan, R., Devenney, E., Dobson-Stone, C., Kwok, J., Hodges, J., Kiernan, M., Halliday, G., Hornberger, M. (2014). Cerebellar Integrity in the Amyotrophic Lateral Sclerosis - Frontotemporal Dementia Continuum. PloS One, 9(8), e105632. [More Information]
  • Davies, K., Bohic, S., Carmona, A., Ortega, R., Cottam, V., Hare, D., Finberg, J., Reyes, S., Halliday, G., Mercer, J., Double, K. (2014). Copper pathology in vulnerable brain regions in Parkinson's disease. Neurobiology of Aging, 35(4), 858-866. [More Information]
  • Stoessl, A., Halliday, G. (2014). DAT-SPECT diagnoses dopamine depletion, but not PD. Movement Disorders, 29(14), 1705-1706. [More Information]
  • Blennerhassett, R., Lillo, P., Halliday, G., Hodges, J., Kril, J. (2014). Distribution of Pathology in Frontal Variant Alzheimer's Disease. Journal of Alzheimer's Disease, 39(1), 63-70. [More Information]
  • Coupland, K., Mellick, G., Silburn, P., Mather, K., Armstrong, N., Sachdev, P., Brodaty, H., Huang, Y., Halliday, G., Hallupp, M., et al (2014). DNA methylation of the MAPT gene in Parkinson's disease cohorts and modulation by vitamin E in vitro. Movement Disorders, 29(13), 1606-1614. [More Information]
  • Wong, J., Halliday, G., Kim, W. (2014). Exploring myelin dysfunction in multiple system atrophy. Experimental Neurobiology, 23(4), 337-344. [More Information]
  • Ferrari, R., Hernandez, D., Nalls, M., Rohrer, J., Ramasamy, A., Kwok, J., Dobson-Stone, C., Brooks, W., Schofield, P., Halliday, G., et al (2014). Frontotemporal dementia and its subtypes: A genome-wide association study. The Lancet Neurology, 13(7), 686-699. [More Information]
  • Bras, J., Guerreiro, R., Darwent, L., Ansorge, O., Escott-Price, V., Hernandez, D., Nalls, M., Clark, L., Honig, L., Halliday, G., et al (2014). Genetic analysis implicates APOE, SNCA and suggests lysosomal dysfunction in the etiology of dementia with Lewy bodies. Human Molecular Genetics, 23(23), 6139-6146. [More Information]
  • Murphy, K., Halliday, G. (2014). Glucocerebrosidase deficits in sporadic Parkinson disease. Autophagy, 10(7), 1350-1351. [More Information]
  • Po, K., Leslie, F., Gracia, N., Bartley, L., Kwok, J., Halliday, G., Hodges, J., Burrell, J. (2014). Heritability in frontotemporal dementia: more missing pieces? Journal of Neurology, 261(11), 2170-2177. [More Information]
  • Hall, H., Reyes, S., Landeck, N., Bye, C., Leanza, G., Double, K., Thompson, L., Halliday, G., Kirik, D. (2014). Hippocampal Lewy pathology and cholinergic dysfunction are associated with dementia in Parkinson's disease. Brain, 137(9), 2493-2508. [More Information]
  • Howitt, J., Gysbers, A., Ayton, S., Carew-Jones, F., Putz, U., Finkelstein, D., Halliday, G., Tan, S. (2014). Increased Ndfip1 in the substantia nigra of parkinsonian brains is associated with elevated iron levels. PloS One, 9(1), 1-7. [More Information]
  • Bleasel, J., Wong, J., Halliday, G., Kim, W. (2014). Lipid dysfunction and pathogenesis of multiple system atrophy. Acta Neuropathologica Communications, 2, 1-11. [More Information]
  • Lam, B., Halliday, G., Irish, M., Hodges, J., Piguet, O. (2014). Longitudinal white matter changes in frontotemporal dementia subtypes. Human Brain Mapping, 35(7), 3547-3557. [More Information]
  • Kordower, J., Halliday, G. (2014). Misfolded proteins in Huntington disease fetal grafts: further evidence of cell-to-cell transfer? Annals of Neurology, 76(1), 20-21. [More Information]
  • Chare, L., Hodges, J., Leyton, C., McGinley, C., Tan, R., Kril, J., Halliday, G. (2014). New criteria for frontotemporal dementia syndromes: clinical and pathological diagnostic implications. Journal of Neurology, Neurosurgery and Psychiatry, 85(8), 865-870.
  • Chare, L., Hodges, J., Leyton, C., McGinley, C., Tan, R., Kril, J., Halliday, G. (2014). New criteria for frontotemporal dementia syndromes: clinical and pathological diagnostic implications. Journal of Neurology, Neurosurgery and Psychiatry, 85(8), 866-871. [More Information]
  • Dzamko, N., Zhou, J., Huang, Y., Halliday, G. (2014). Parkinson's disease-implicated kinases in the brain; insights into disease pathogenesis. Frontiers in Molecular Neuroscience, 7, 1-15. [More Information]
  • Kragh, C., Gysbers, A., Rockenstein, E., Murphy, K., Halliday, G., Masliah, E., Jensen, P. (2014). Prodegenerative IkBa expression in oligodendroglial a-synuclein models of multiple system atrophy. Neurobiology of Disease, 63, 171-183. [More Information]
  • Murphy, K., Gysbers, A., Abbott, S., Tayebi, N., Kim, W., Sidransky, E., Cooper, A., Garner, B., Halliday, G. (2014). Reduced glucocerebrosidase is associated with increased alpha-synuclein in sporadic Parkinson's disease. Brain, 137(3), 834-848. [More Information]
  • Ahmed, R., MacMillan, M., Bartley, L., Halliday, G., Kiernan, M., Hodges, J., Piguet, O. (2014). Systemic metabolism in frontotemporal dementia. Neurology, 83, 1812-1818. [More Information]
  • Riley, B., Gardai, S., Emig-Agius, D., Bessarabova, M., Ivliev, A., Schule, B., Alexander, J., Wallace, W., Halliday, G., et al (2014). Systems-based analyses of brain regions functionally impacted in Parkinson's disease reveals underlying causal mechanisms. PloS One, 9(8), 1-14. [More Information]
  • Halliday, G., Leverenz, J., Schneider, J., Adler, C. (2014). The neurobiological basis of cognitive impairment in Parkinson's disease. Movement Disorders, 29(5), 634-650. [More Information]
  • Stevens, C., Halliday, G. (2014). The role of astrocytes in parkinson's disease. Inflammation in Parkinson's Disease: Scientific and Clinical Aspects, (pp. 127-144). Cham: Springer International Publishing Switzerland. [More Information]
  • Shine, J., Halliday, G., Gilat, M., Matar, E., Bolitho, S., Carlos, M., Naismith, S., Lewis, S. (2014). The role of dysfunctional attentional control networks in visual misperceptions in Parkinson's disease. Human Brain Mapping, 35(5), 2206-2219. [More Information]
  • Berg, D., Postuma, R., Bloem, B., Dubois, B., Gasser, T., Goetz, C., Halliday, G., Hardy, J., Lang, A., Litvan, I., et al (2014). Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson's disease. Movement Disorders, 29(4), 454-462. [More Information]
  • Gallagher, M., Suh, E., Grossman, M., Elman, L., McCluskey, L., van Swieten, J., Al‑Sarraj, S., Neumann, M., Halliday, G., Kril, J., et al (2014). TMEM106B is a genetic modifier of frontotemporal lobar degeneration with C9orf72 hexanucleotide repeat expansions. Acta Neuropathologica, 127(3), 407-418. [More Information]
  • Shine, J., O'Callaghan, C., Halliday, G., Lewis, S. (2014). Tricks of the mind: Visual hallucinations as disorders of attention. Progress in Neurobiology, 116, 58-65. [More Information]
  • Muller, A., Shine, J., Halliday, G., Lewis, S. (2014). Visual hallucinations in Parkinson's disease: Theoretical models. Movement Disorders, 29(13), 1591-1598. [More Information]

2013

  • Nalls, M., Duran, R., Lopez, G., Kurzawa-Akanbi, M., McKeith, I., Chinnery, P., Morris, C., Theuns, J., Crosiers, D., Cras, P., et al (2013). A multicenter study of glucocerebrosidase mutations in dementia with Lewy bodies. JAMA Neurology, 70(6), 727-735. [More Information]
  • Kim, W., Hsiao, J., Bhatia, S., Glaros, E., Don, A., Tsuruoka, S., Weickert, C., Halliday, G. (2013). ABCA8 stimulates sphingomyelin production in oligodendrocytes. Biochemical Journal, 452(3), 401-410. [More Information]
  • Abbott, S., Jenner, A., Mitchell, T., Brown, S., Halliday, G., Garner, B. (2013). An improved high-throughput lipid extraction method for the analysis of human brain lipids. Lipids, 48(3), 307-318. [More Information]
  • Dickson, P., Shehadeh, J., Double, K., Bobrovskaya, L., Reyes, S., Dunkley, P., Halliday, G. (2013). Analysis of Tyrosine Hydroxylase Isoforms and Phosphorylation in Parkinson's Disease. In Lee E. Eiden (Eds.), Catecholamine Research in the 21st Century: Abstracts and Graphical Abstracts, 10th International Catecholamine Symposium, 2012, (pp. 15-15). London: Elsevier. [More Information]
  • Murphy, K., Cottle, L., Gysbers, A., Cooper, A., Halliday, G. (2013). ATP13A2 (PARK9) protein levels are reduced in brain tissue of cases with Lewy bodies. Acta Neuropathologica Communications, 1(1), 1-8. [More Information]
  • Huang, Y., Halliday, G. (2013). Can we clinically diagnose dementia with Lewy bodies yet? Translational Neurodegeneration, 2(1), 1-9. [More Information]
  • Tan, R., Shepherd, C., Kril, J., McCann, H., McGeachie, A., McGinley, C., Affleck, A., Halliday, G. (2013). Classification of FTLD-TDP cases into pathological subtypes using antibodies against phosphorylated and non-phosphorylated TDP43. Acta Neuropathologica Communications, 1(1), 1-9. [More Information]
  • Kemp, S., Harding, A., Halliday, G., Mahant, N., Fung, V. (2013). Cortical limb myoclonus in pathologically proven progressive supranuclear palsy. Movement Disorders, 28(13), 1804-1806. [More Information]
  • Kordower, J., Olanow, C., Dodiya, H., Chu, Y., Beach, T., Adler, C., Halliday, G., Bartus, R. (2013). Disease duration and the integrity of the nigrostriatal system in Parkinson's disease. Brain, 136(8), 2419-2431. [More Information]
  • Wang, J., Gouda-Vossos, A., Dzamko, N., Halliday, G., Huang, Y. (2013). DNA extraction from fresh-frozen and formalin-fixed, paraffinembedded human brain tissue. Neuroscience Bulletin, 29(5), 649-654. [More Information]
  • Hsiao, J., Fu, Y., Hill, A., Halliday, G., Kim, W. (2013). Elevation in Sphingomyelin Synthase Activity Is Associated with Increases in Amyloid-Beta Peptide Generation. PloS One, 8(8). [More Information]
  • Dang, T., Dobson-Stone, C., Glaros, E., Kim, W., Hallupp, M., Bartley, L., Piguet, O., Hodges, J., Halliday, G., Double, K., et al (2013). Endogenous progesterone levels and frontotemporal dementia: Modulation of TDP-43 and Tau levels in vitro and treatment of the A315T TARDBP mouse model. Disease Models and Mechanisms, 6(5), 1198-1204. [More Information]
  • Kragh, C., Fillon, G., Gysbers, A., Hansen, H., Neumann, M., Richter-Landsberg, C., Zalc, B., Lubetzki, C., Gai, W., Halliday, G., et al (2013). FAS-Dependent Cell Death in ?-Synuclein Transgenic Oligodendrocyte Models of Multiple System Atrophy. PloS One, 8(1), 1-9. [More Information]
  • Dobson-Stone, C., Thompson, E., Luty, A., Blumbergs, P., Brooks, W., Short, C., Field, C., Panegyres, P., Hecker, J., Halliday, G., et al (2013). Frontotemporal dementia-amyotrophic lateral sclerosis syndrome locus on chromosome 16p12.1-q12.2: Genetic, clinical and neuropathological analysis. Acta Neuropathologica, 125(4), 523-533. [More Information]
  • Bleasel, J., Hsiao, J., Halliday, G., Kim, W. (2013). Increased expression of ABCA8 in multiple system atrophy brain is associated with changes in pathogenic proteins. Journal of Parkinson's Disease, 3(3), 331-339. [More Information]
  • Cheshire, P., Bertram, K., Ling, H., O'Sullivan, S., Halliday, G., McLean, C., Bras, J., Foltynie, T., Storey, E., Williams, D. (2013). Influence of single nucleotide polymorphisms in COMT, MAO-A and BDNF genes on dyskinesias and levodopa use in Parkinson's disease. Neurodegenerative Diseases, 13(1), 24-28. [More Information]
  • Davies, K., Hare, D., Cottam, V., Chen, N., Hilgers, L., Halliday, G., Mercer, J., Double, K. (2013). Localization of copper and copper transporters in the human brain. Metallomics, 5(1), 43-51. [More Information]
  • Guerreiro, P., Huang, Y., Gysbers, A., Cheng, D., Gai, W., Outeiro, T., Halliday, G. (2013). LRRK2 interactions with ?-synuclein in Parkinson's disease brains and in cell models. Journal of Molecular Medicine, 91(4), 513-522. [More Information]
  • Dzamko, N., Chua, G., Ranola, M., Rowe, D., Halliday, G. (2013). Measurement of LRRK2 and Ser910/935 phosphorylated LRRK2 in peripheral blood mononuclear cells from idiopathic Parkinson's disease patients. Journal of Parkinson's Disease, 3(2), 145-152. [More Information]
  • Halliday, G. (2013). Motor deficits associated with changes in β-amyloid in Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry, 84(5), 475-476. [More Information]
  • Ravenscroft, T., Baker, M., Rutherford, N., Neumann, M., Mackenzie, I., Josephs, K., Boeve, B., Petersen, R., Halliday, G., Kril, J., et al (2013). Mutations in protein N-arginine methyltransferases are not the cause of FTLD-FUS. Neurobiology of Aging, 34(9), 2235.e11-2235.e13. [More Information]
  • Kavanagh, T., Mills, J., Kim, W., Halliday, G., Janitz, M. (2013). Pathway analysis of the human brain transcriptome in disease. Journal of Molecular Neuroscience, 51(1), 28-36. [More Information]
  • Tan, R., Wong, S., Hodges, J., Halliday, G., Hornberger, M. (2013). Retrosplenial cortex (BA 29) volumes in behavioral variant frontotemporal dementia and alzheimer's disease. Dementia and Geriatric Cognitive Disorders, 35(3-4), 177-182. [More Information]
  • Zhou, J., Zhang, H., Huang, Y., He, Y., Anderson, J., Gai, W., Liang, Z., Wang, Y., Ren, X., Halliday, G., et al (2013). Tenuigenin attenuates alpha-synuclein-induced cytotoxicity by down-regulating polo-like kinase 3. CNS Neuroscience and Therapeutics, 19(9), 688-694. [More Information]
  • Tan, R., Pok, K., Wong, S., Brooks, D., Halliday, G., Kril, J. (2013). The pathogenesis of cingulate atrophy in behavioral variant frontotemporal dementia and Alzheimer's disease. Acta Neuropathologica Communications, 1(30), 1-6. [More Information]
  • Reyes, S., Fu, Y., Double, K., Cottam, V., Thompson, L., Kirik, D., Paxinos, G., Watson, C., Cooper, H., Halliday, G. (2013). Trophic factors differentiate dopamine neurons vulnerable to Parkinson's disease. Neurobiology of Aging, 34(3), 873-886. [More Information]
  • Mills, J., Kavanagh, T., Kim, W., Chen, B., Kawahara, Y., Halliday, G., Janitz, M. (2013). Unique Transcriptome Patterns of the White and Grey Matter Corroborate Structural and Functional Heterogeneity in the Human Frontal Lobe. PloS One, 8(10), 1-18. [More Information]
  • Dzamko, N., Halliday, G. (2013). Unlocking the secrets of LRRK2 function with selective kinase inhibitors. Future Neurology, 8(3), 347-357. [More Information]

2012

  • Fu, Y., Yuan, Y., Halliday, G., Rusznak, Z., Watson, C., Paxinos, G. (2012). A cytoarchitectonic and chemoarchitectonic analysis of the dopamine cell groups in the substantia nigra, ventral tegmental area, and retrorubral field in the mouse. Brain Structure and Function, 217(2), 591-612. [More Information]
  • Wong, J., Higgins, M., Halliday, G., Garner, B. (2012). Amyloid beta selectively modulates neuronal TrkB alternative transcript expression with implications for Alzheimer's disease. Neuroscience, 210, 363-374. [More Information]
  • Dzamko, N., Halliday, G. (2012). An emerging role for LRRK2 in the immune system. Biochemical Society Transactions, 40(5), 1134-1139. [More Information]
  • Halliday, G. (2012). An evidence base for noradrenergic deficits in Parkinson's disease. Movement Disorders, 27(13), 1589-1591. [More Information]
  • Lewis, S., Shine, J., Duffy, S., Halliday, G., Naismith, S. (2012). Anterior Cingulate Integrity: Executive and Neuropsychiatric Features in Parkinson's Disease. Movement Disorders, 27(10), 1262-1267. [More Information]
  • Huang, Y., Halliday, G. (2012). Aspects of innate immunity and Parkinson's disease. Frontiers in Pharmacology, 3, 1-10. [More Information]
  • Dobson-Stone, C., Hallupp, M., Bartley, L., Shepherd, C., Halliday, G., Schofield, P., Hodges, J., Kwok, J. (2012). C9ORF72 repeat expansion in clinical and neuropathologic frontotemporal dementia cohorts. Neurology, 79(10), 995-1001. [More Information]
  • Kim, W., Halliday, G. (2012). Changes in sphingomyelin level affect alpha-synuclein and ABCA5 expression. Journal of Parkinson's Disease, 2(1), 41-46. [More Information]
  • Halliday, G., McCann, H., Shepherd, C. (2012). Evaluation of the Braak hypothesis: How far can it explain the pathogenesis of Parkinson's disease? Expert Review of Neurotherapeutics, 12(6), 673-686. [More Information]
  • Reyes, S., Fu, Y., Double, K., Thompson, L., Kirik, D., Paxinos, G., Halliday, G. (2012). GIRK2 expression in dopamine neurons of the substantia nigra and ventral tegmental area. The Journal of Comparative Neurology, 520(12), 2591-2607. [More Information]
  • Hornberger, M., Wong, S., Tan, R., Irish, M., Piguet, O., Kril, J., Hodges, J., Halliday, G. (2012). In vivo and post-mortem memory circuit integrity in frontotemporal dementia and Alzheimer's disease. Brain, 135(10), 3015-3025. [More Information]
  • Shine, J., Halliday, G., Carlos, M., Naismith, S., Lewis, S. (2012). Investigating Visual Misperceptions in Parkinson's Disease: A Novel Behavioral Paradigm. Movement Disorders, 27(4), 500-505. [More Information]
  • Sharpe, L., Wong, J., Garner, B., Halliday, G., Brown, A. (2012). Is seladin-1 really a selective alzheimer's disease indicator? Journal of Alzheimer's Disease, 30(1), 35-39. [More Information]
  • Elliott, D., Kim, W., Gorrisen, S., Halliday, G., Kwok, J. (2012). Leucine-rich repeat kinase 2 and alternative splicing in Parkinson's disease. Movement Disorders, 27(8), 1004-1011. [More Information]
  • Huang, Y., Chegini, F., Chua, G., Murphy, K., Gai, W., Halliday, G. (2012). Macroautophagy in sporadic and the genetic form of Parkinson's disease with the A53T ?-synuclein mutation. Translational Neurodegeneration, 1, 1-7. [More Information]
  • Halliday, G., Bigio, E., Cairns, N., Neumann, M., Mackenzie, I., Mann, D. (2012). Mechanisms of disease in frontotemporal lobar degeneration: Gain of function versus loss of function effects. Acta Neuropathologica, 124(3), 373-382. [More Information]
  • Valenzuela, M., Matthews, F., Brayne, C., Ince, P., Halliday, G., Kril, J., Dalton, M., Richardson, K., Forster, G., Sachdev, P. (2012). Multiple Biological Pathways Link Cognitive Lifestyle to Protection from Dementia. Biological Psychiatry, 71(9), 783-791. [More Information]
  • Stevens, C., Rowe, D., Morel-Kopp, M., Orr, C., Russell, T., Ranola, M., Ward, C., Halliday, G. (2012). Reduced T helper and B lymphocytes in Parkinson's disease. Journal of Neuroimmunology, 252(1-2), 95-99. [More Information]
  • Lim, Y., Giese, M., Shepherd, C., Halliday, G., Kobayashi, M., Takamatsu, K., Staufenbiel, M., Eckert, A., Goetz, J. (2012). Role of hippocalcin in mediating AB toxicity. Biochimica et Biophysica Acta. Molecular and Cell Biology of Lipids, 1822 (8), 1247-1257. [More Information]
  • Schwartz, R., Halliday, G., Cordato, D., Kril, J. (2012). Small-Vessel Disease in Patients with Parkinson's Disease: A Clinicopathological Study. Movement Disorders, 27(12), 1506-1512. [More Information]
  • Wong, J., Garner, B., Halliday, G., Kwok, J. (2012). Srp20 regulates TrkB pre-mRNA splicing to generate TrkB-Shc transcripts with implications for Alzheimer's disease. Journal of Neurochemistry, 123(1), 159-171. [More Information]
  • Double, K., Halliday, G., Reyes, S. (2012). Substantia Nigra, Ventral Tegmental Area and Retrorubral Fields. In Juergen K. Mai and George Paxinos (Eds.), The Human Nervous System, (pp. 439-455). London: Academic Press.
  • Halliday, G., Reyes, S., Double, K. (2012). Substantia Nigra, Ventral Tegmental Area, and Retrorubral Fields. In Juergen K. Mai and George Paxinos (Eds.), The Human Nervous System, (pp. 439-455). London: Academic Press. [More Information]
  • Schofield, E., Hodges, J., Bak, T., Xuereb, J., Halliday, G. (2012). The relationship between clinical and pathological variables in Richardson's syndrome. Journal of Neurology, 259(3), 482-490. [More Information]

2011

  • Zhou, J., Broe, M., Huang, Y., Anderson, J., Gai, W., Milward, E., Porritt, M., Howells, D., Hughes, A., Wang, X., et al (2011). Changes in the solubility and phosphorylation of alpha-synuclein over the course of Parkinson's disease. Acta Neuropathologica, 121(6), 695-704. [More Information]
  • Song, Y., Huang, Y., Halliday, G. (2011). Clinical correlates of similar pathologies in parkinsonian syndromes. Movement Disorders, 26(3), 499-506. [More Information]
  • Piguet, O., Halliday, G., Reid, W., Casey, B., Carman, R., Huang, Y., Xuereb, J., Hodges, J., Kril, J. (2011). Clinical phenotypes in autopsy-confirmed Pick disease. Neurology, 76(3), 253-259. [More Information]
  • Sachdev, P., Lee, T., Lammel, A., Crawford, J., Trollor, J., Wright, M., Brodaty, H., Ames, D., Halliday, G., et al (2011). Cognitive functioning in older twins: The Older Australian Twins Study. Australasian Journal on Ageing, 30(SUPPL 2), 17-23. [More Information]
  • Schofield, E., Hodges, J., Macdonald, V., Cordato, N., Kril, J., Halliday, G. (2011). Cortical Atrophy Differentiates Richardson's Syndrome from the Parkinsonian Form of Progressive Supranuclear Palsy. Movement Disorders, 26(2), 256-263. [More Information]
  • Reid, W., Hely, M., Morris, J., Loy, C., Halliday, G. (2011). Dementia in Parkinson's disease: a 20-year neuropsychological study (Sydney Multicentre Study). Journal of Neurology, Neurosurgery and Psychiatry, 82(9), 1033-1037. [More Information]
  • Piguet, O., Petersen, A., Lam, B., Gabery, S., Murphy, K., Hodges, J., Halliday, G. (2011). Eating and hypothalamus changes in behavioral-variant frontotemporal dementia. Annals of Neurology, 69(2), 312-319. [More Information]
  • Huang, Y., Zheng, L., Halliday, G., Dobson-Stone, C., Wang, Y., Tang, H., Cao, L., Deng, Y., Wang, G., Zhang, Y., et al (2011). Genetic polymorphisms in sigma-1 receptor and apolipoprotein E interact to influence the severity of alzheimer's disease. Current Alzheimer Research, 8(7), 765-770. [More Information]
  • Halliday, G., Stevens, C. (2011). Glia: Initiators and progressors of pathology in Parkinson's disease. Movement Disorders, 26(1), 6-17. [More Information]
  • Huang, Y., Rowe, D., Halliday, G. (2011). Interaction between a-synuclein and tau genotypes and the progression of Parkinson's disease. Journal of Parkinson's Disease, 1(3), 271-276. [More Information]
  • Elliott, D., Tsoi, K., Holinkova, S., Chan, S., Kim, W., Halliday, G., Rye, K., Garner, B. (2011). Isoform-specific proteolysis of apolipoprotein-E in the brain. Neurobiology of Aging, 32(2), 257-271. [More Information]
  • Cheng, D., Jenner, A., Shui, G., Cheong, W., Mitchell, T., Nealon, J., Kim, W., McCann, H., Wenk, M., Halliday, G., et al (2011). Lipid pathway alterations in parkinson's disease primary visual cortex. PloS One, 6(2), 1-17. [More Information]
  • Halliday, G., Lees, A., Stern, M. (2011). Milestones in Parkinson's disease-Clinical and pathologic features. Movement Disorders, 26(6), 1015-1021. [More Information]
  • Halliday, G., Holton, J., Revesz, T., Dickson, D. (2011). Neuropathology underlying clinical variability in patients with synucleinopathies. Acta Neuropathologica, 122(2), 187-204. [More Information]
  • Masters, C., Kril, J., Halliday, G., Pamphlett, R., Collins, S., Hill, A., McLean, C. (2011). Overview and recent advances in neuropathology. Part 2: Neurodegeneration. Journal of Pathology, 43(2), 93-102. [More Information]
  • Kril, J., Halliday, G. (2011). Pathological Staging of Frontotemporal Lobar Degeneration. Journal of Molecular Neuroscience, 45(3), 379-383. [More Information]
  • Halliday, G., Song, C., Harding, A. (2011). Striatal β-amyloid in dementia with Lewy bodies but not Parkinson's disease. Journal of Neural Transmission, 118(5), 713-719. [More Information]
  • Komadina, N., Terpening, Z., Huang, Y., Halliday, G., Naismith, S., Lewis, S. (2011). Utility and Limitations of Addenbrooke's Cognitive Examination-Revised for Detecting Mild Cognitive Impairment in Parkinson's Disease. Dementia and Geriatric Cognitive Disorders, 31(5), 349-357. [More Information]
  • Shine, J., Halliday, G., Naismith, S., Lewis, S. (2011). Visual misperceptions and hallucinations in Parkinson's disease: Dysfunction of attentional control networks? Movement Disorders, 26(12), 2154-2159. [More Information]

2010

  • Gabery, S., Murphy, K., Schultz, K., Loy, C., McCusker, E., Kirik, D., Halliday, G., Petersen, A. (2010). Changes in Key Hypothalamic Neuropeptide Populations in Huntington Disease Revealed by Neuropathological Analyses. Acta Neophilologica, 120, 777-788. [More Information]
  • Werry, E., Enjeti, S., Halliday, G., Sachdev, P., Double, K. (2010). Effect of age on proliferation-regulating factors in human adult neurogenic areas. Journal of Neurochemistry, 115(4), 956-964. [More Information]
  • Schofield, E., Halliday, G., Kwok, J., Loy, C., Double, K., Hodges, J. (2010). Low Serum Progranulin Predicts the Presence of Mutations: A Prospective Study. Journal of Alzheimer's Disease, 22(3), 981-984. [More Information]
  • Mackenzie, I., Neumann, M., Bigio, E., Cairns, N., Alafuzoff, I., Kril, J., Kovacs, G., Ghetti, B., Halliday, G., Holm, I., et al (2010). Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an update. Acta Neuropathologica, 119(1), 1-4. [More Information]
  • Luty, A., Kwok, J., Dobson-Stone, C., Loy, C., Coupland, K., Karlstrom, H., Sobow, T., Tchorzewska, J., Maruszak, A., Barcikowsk, M., Blair, I., et al (2010). Sigma Nonopioid Intracellular Receptor 1 Mutations Cause Frontotemporal Lobar Degeneration-Motor Neuron Disease. Annals of Neurology, 68(5), 639-649. [More Information]
  • Loy, C., Kril, J., Trollor, J., Kiernan, M., Kwok, J., Vucic, S., Halliday, G., Hodges, J. (2010). The case of a 48 year-old woman with bizarre and complex delusions. Nature Reviews Neurology, 6(3), 175-179. [More Information]

2009

  • Double, K., Rowe, D., Carew-Jones, F., Hayes, M., Chan, D., Blackie, J., Corbett, A., Joffe, R., Fung, V., Morris, J., et al (2009). Anti-melanin antibodies are increased in sera in Parkinson's disease. Experimental Neurology, 217, 297-301. [More Information]
  • Piguet, O., Halliday, G., Creasey, H., Broe, G., Kril, J. (2009). Frontotemporal dementia and dementia with Lewy bodies in a case-control study of Alzheimer's disease. International Psychogeriatrics, 21(4), 688-695. [More Information]
  • Mehta, P., Mellick, G., Rowe, D., Halliday, G., Jones, M., Manwaring, N., Vandebona, H., Silburn, P., Wang, J., Mitchell, P., Sue, C. (2009). Mitochondrial DNA Haplogroups J and K are not Protective for Parkinson's Disease in the Australian Community. Movement Disorders, 24(2), 290-292. [More Information]
  • Monoranu, C., Apfelbacher, M., Grunblatt, E., Puppe, B., Alafuzoff, I., Ferrer, I., Al-Saraj, S., Keyvani, K., Schmitt, A., Falkai, P., Kril, J., Harper, C., et al (2009). pH measurement as quality control on human post mortem brain tissue: a study of the BrainNet Europe consortium. Neuropathology and Applied Neurobiology, 35(3), 329-337. [More Information]
  • Van Eersel, J., Bi, M., Ke, Y., Hodges, J., Xuereb, J., Gregory, G., Halliday, G., Goetz, J., Kril, J., Ittner, L. (2009). Phosphorylation of soluble tau differs in Pick's disease and Alzheimer's disease brains. Journal of Neural Transmission, 116(10), 1243-1251. [More Information]
  • Truong, L., Brooks, D., Amaral, F., Henderson, J., Halliday, G. (2009). Relative preservation of thalamic centromedian nucleus in parkinsonian patients with dystonia. Movement Disorders, 24(14), 2128-2135. [More Information]
  • Kril, J., Davis, R., Halliday, G., Xuereb, J., Hodges, J. (2009). The neural basis of semantic memory: Evidence from semantic dementia. Neurobiology of Aging, 30(12), 2043-2052. [More Information]
  • Piguet, O., Double, K., Kril, J., Harasty, J., Macdonald, V., McRitchie, D., Halliday, G. (2009). White matter loss in healthy ageing: A postmortem analysis. Neurobiology of Aging, 30(8), 1288-1295. [More Information]

2008

  • Sutherland, G., Mellick, G., Newman, J., Double, K., Stevens, J., Lee, L., Rowe, D., Silburn, P., Halliday, G. (2008). Haplotype analysis of the IGF2-INS-TH gene cluster in Parkinson's disease. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 147B (4), 495-499. [More Information]
  • Young, V., Halliday, G., Kril, J. (2008). Neuropathologic correlates of white matter hyperintensities. Neurology, 71(11), 804-811. [More Information]
  • Luty, A., Kwok, J., Thompson, E., Blumbergs, P., Brooks, W., Loy, C., Dobson-Stone, C., Panegyres, P., Hecker, J., Nicholson, G., et al (2008). Pedigree with frontotemporal lobar degeneration--motor neuron disease and Tar DNA binding protein-43 positive neuropathology: genetic linkage to chromosome 9. BMC Neurology, 8(32), 1-11. [More Information]
  • Double, K., Dedov, V., Fedorow, H., Kettle, E., Halliday, G., Garner, B., Brunk, U. (2008). The comparative biology of neuromelanin and lipofuscin in the human brain. Cellular and Molecular Life Sciences, 65, 1669-1682. [More Information]
  • Halliday, G., Hely, M., Reid, W., Morris, J. (2008). The progression of pathology in longitudinally followed patients with Parkinson's disease. Acta Neuropathologica, 115(4), 409-415. [More Information]
  • Hely, M., Reid, W., Adena, M., Halliday, G., Morris, J. (2008). The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years. Movement Disorders, 23(6), 837-844. [More Information]
  • Karlstrom, H., Brooks, W., Kwok, J., Broe, G., Kril, J., McCann, H., Halliday, G., Schofield, P. (2008). Variable phenotype of Alzheimer's disease with spastic paraparesis. Journal of Neurochemistry, 104(3), 573-583. [More Information]

2007

  • Sutherland, G., Mellick, G., Sue, C., Chan, D., Rowe, D., Silburn, P., Halliday, G. (2007). A functional polymorphism in the parkin gene promoter affects the age of onset of Parkinson's disease. Neuroscience Letters, 414(2), 170-173. [More Information]
  • Kipps, C., Davies, R., Mitchell, J., Kril, J., Halliday, G., Hodges, J. (2007). Clinical significance of lobar atrophy in frontotemporal dementia: application of an MRI visual rating scale. Dementia and Geriatric Cognitive Disorders, 23(5), 334-342. [More Information]
  • Kipps, C., Davies, R., Mitchell, J., Kril, J., Halliday, G., Hodges, J. (2007). Clinical significance of lobar atrophy in frontotemporal dementia: Application of an MRI visual rating scale. Dementia and Geriatric Cognitive Disorders, 23(5), 334-342. [More Information]
  • Gupta, R., Dixon, K., Deo, S., Holliday, C., Slater, M., Halliday, G., Reeve, V., Mason, R. (2007). Photoprotection by 1,25 Dihydroxyvitamin D3 Is Associated with an Increase in p53 and a Decrease in Nitric Oxide Products. Journal of Investigative Dermatology, 127(3), 707-715. [More Information]
  • Huang, Y., Halliday, G., Vandebona, H., Mellick, G., Mastaglia, F., Stevens, J., Kwok, J., Garlepp, M., Silburn, P., Horne, M., Rowe, D., Sue, C., et al (2007). Prevalence and clinical features of common LRRK2 mutations in Australians with Parkinson's disease. Movement Disorders, 22(7), 982-989. [More Information]
  • Sutherland, G., Nowak, G., Halliday, G., Kril, J. (2007). Tau isoform expression in frontotemporal dementia without tau deposition. Journal of Clinical Neuroscience, 14(12), 1182-1185. [More Information]
  • Qi, B., Huang, Y., Rowe, D., Halliday, G. (2007). VISA - A pass to innate immunity. The International Journal of Biochemistry and Cell Biology, 39, 287-291. [More Information]
  • Piguet, O., Double, K., Kril, J., Harasty, J., Macdonald, V., McRitchie, D., Halliday, G. (2007). White matter loss in healthy ageing: A postmortem analysis. Neurobiology of Aging, doi:10.1016/j.neurobiolaging.2007.10.015(30 (8)), 1288-1295. [More Information]

2006

  • Huang, Y., Hayes, M., Harding, A., Brooks, W., Fung, V., Rowe, D., Joffe, R., Crimmins, D., Hely, M., Halliday, G. (2006). Anticipation of onset age in familial Parkinson's disease without SCA gene mutations. Parkinsonism and Related Disorders, 12(5), 309-313. [More Information]
  • Huang, Y., Hayes, M., Harding, A., Brooks, W., Fung, V., Rowe, D., Joffe, R., Crimmins, D., Hely, M., Halliday, G. (2006). Anticipation of onset age in familial Parkinson’s disease without SCA gene mutations. Parkinsonism and Related Disorders, 12, 309-313. [More Information]
  • David, D., Ittner, L., Gehrig, P., Nergenau, D., Shepherd, C., Halliday, G., Goetz, J. (2006). beta-Amyloid treatment of two complementary P301L tau-expressing Alzheimer's disease models reveals similar deregulated cellular processes. Proteomics, 6(24), 6566-6577. [More Information]
  • Bennett, H., Piguet, O., Grayson, D., Creasey, H., Waite, L., Lye, T., Corbett, A., Hayes, M., Broe, G., Halliday, G. (2006). Cognitive, extrapyramidal, and magnetic resonance imaging predictors of functional impairment in nondemented older community dwellers: The Sydney Older Person Study. Journal of the American Geriatrics Society, 54(1), 3-10. [More Information]
  • Cordato, N., Halliday, G., Caine, D., Morris, J. (2006). Comparison of motor, cognitive and behavioural features in progressive supranuclear palsy and Parkinson's disease. Movement Disorders, 21(5), 632-638. [More Information]
  • Cordato, N., Halliday, G., Caine, D., Morris, J. (2006). Comparison of Motor, Cognitive, and Behavioral Features in Progressive Supranuclear Palsy and Parkinson's Disease. Movement Disorders, 21(5), 632-638.
  • Gregory, G., Macdonald, V., Schofield, P., Kril, J., Halliday, G. (2006). Differences in regional brain atrophy in genetic forms of Alzheimer's disease. Neurobiology of Aging, 27(3), 387-393. [More Information]
  • Halliday, G., Fedorow, H., Rickert, C., Gerlach, M., Riederer, P., Double, K. (2006). Evidence for specific phases in the development of human neuromelanin. Journal of Neural Transmission, 113, 721-728. [More Information]
  • Fedorow, H., Pickford, R., Kettle, E., Cartwright, M., Halliday, G., Gerlach, M., Riederer, P., Garner, B., Double, K. (2006). Investigation of the lipid component of neuromelanin. Journal of Neural Transmission, 113, 735-739. [More Information]
  • Pickering-Brown, S., Baker, M., Gass, J., Boeve, B., Loy, C., Brooks, W., Mackenzie, I., Martins, R., Kwok, J., Halliday, G., Kril, J., et al (2006). Mutations in Progranulin explain atypical phenotypes associated with variants in the MAPT. Brain, 129(11), 3124-3126. [More Information]
  • Halliday, G., Song, Y., Creasey, H., Morris, J., Brooks, W., Kril, J. (2006). Neuropathology in the S305S tau gene mutation. Brain, 129(3), 1-5. [More Information]
  • Piguet, O., Bennett, H., Waite, L., Kril, J., Broe, G., Creasey, H., Halliday, G. (2006). Preserved cognition and functional independence after a large right posterior cerebral artery infarct: longitudinal clinical and neuropathological findings. Neurocase, 12(2), 81-90. [More Information]
  • Davies, R., Kipps, C., Mitchell, J., Kril, J., Halliday, G., Hodges, J. (2006). Progression in Frontotemporal Dementia: Identifying a Benign Behavioral Variant by Magnetic Resonance Imaging. JAMA Neurology, 63(11), 1627-1631. [More Information]
  • Kersaitis, C., Halliday, G., Xuereb, J., Pamphlett, R., Bak, T., Hodges, J., Kril, J. (2006). Ubiquitin-positive inclusions and progression of pathology in frontotemporal dementia and motor neurone disease identifies a group with mainly early pathology. Neuropathology and Applied Neurobiology, 32(1), 83-91. [More Information]

2005

  • Orr, C., Rowe, D., Mizuno, Y., Mori, H., Halliday, G. (2005). A possible role for humoral immunity in the pathogenesis of Parkinson's disease. Brain, 128(11), 2665-2674. [More Information]
  • Cordato, N., Duggins, A., Halliday, G., Morris, J., Pantelis, C. (2005). Clinical deficits correlate with regional cerebral atrophy in progressive supranuclear palsy. Brain, 128(6), 1259-1266. [More Information]
  • Kril, J., Macdonald, V., Patel, S., Png, F., Halliday, G. (2005). Distribution of brain atrophy in behavioral variant frontotemporal dementia. Journal of the Neurological Sciences, 232(1-2), 83-90. [More Information]
  • Fedorow, H., Pickford, R., Hook, J., Double, K., Halliday, G., Gerlach, M., Riederer, P., Garner, B. (2005). Dolichol is the major lipid component of human substantia nigra neuromelanin. Journal of Neurochemistry, 92, 990-995. [More Information]
  • Kwok, J., Hallupp, M., Loy, C., Chan, D., Woo, J., Mellick, G., Buchanan, D., Silburn, P., Halliday, G., Schofield, P. (2005). GSK3B polymorphisms alter transcription and splicing in Parkinson's disease. Annals of Neurology, 58(6), 829-839. [More Information]
  • Osborne, P., Halliday, G., Cooper, H., Keast, J. (2005). Localization of immunoreactivity for deleted in colorectal cancer (DCC), the receptor for the guidance factor netrin-1, in ventral tier dopamine projection pathways in adult rodents. Neuroscience, 131(3), 671-681. [More Information]
  • Fedorow, H., Tribl, F., Halliday, G., Gerlach, M., Riederer, P., Double, K. (2005). Neuromelanin in human dopamine neurons: Comparison with peripheral melanins and relevance to Parkinson’s disease. Progress in Neurobiology, 75, 109-124. [More Information]
  • Huang, Y., Garrick, R., Cook, R., O'Sullivan, D., Morris, J., Halliday, G. (2005). Pallidal stimulation reduces treatment-induced dyskinesias in "minimal-change" multiple system atrophy. Movement Disorders, 20(8), 1042-1047. [More Information]
  • Graham, A., Davies, R., Xuereb, J., Halliday, G., Kril, J., Creasey, H., Graham, K., Hodges, J. (2005). Pathologically proven frontotemporal dementia presenting with severe amnesia. Brain, 128(3), 597-605. [More Information]
  • Raftery, M., Campbell, R., Glaros, E., Rye, K., Halliday, G., Jessup, W., Garner, B. (2005). Phosphorylation of Apolipoprotein-E at an Atypical Protein Kinase CK2 PSD/E Site in Vitro. Biochemistry, 44(19), 7346-7353. [More Information]
  • Halliday, G., Song, Y., Lepar, G., Brooks, W., Kwok, J., Kersaitis, C., Gregory, G., Shepherd, C., Rahimi, F., Schofield, P., Kril, J. (2005). Pick bodies in a family with presenilin-1 Alzheimer's disease. Annals of Neurology, 57(1), 139-143. [More Information]
  • Schofield, E., Caine, D., Kril, J., Cordato, N., Halliday, G. (2005). Staging Disease Severity in Movement Disorder Tauopathies: Brain Atrophy Separates Progressive Supranuclear Palsy From Corticobasal Degeneration. Movement Disorders, 20(1), 34-39. [More Information]
  • Henderson, J., Halliday, G., Macdonald, V. (2005). Thalamic And Cortical Changes in Parkinsonian Disorders. The Basal Ganglia VIII, UK: Springer.
  • Davies, R., Hodges, J., Kril, J., Patterson, K., Halliday, G., Xuereb, J. (2005). The pathological basis of semantic dementia. Brain, 128(Part 9), 1984-1995. [More Information]
  • Kril, J., Karlstrom, H., Brooks, W., Kwok, J., Halliday, G., Schofield, P. (2005). Variable phenotype of Alzheimer's disease with spastic paraparesis. In Cummings J; Hardy J; Poncet M; Christen Y (Eds.), Genotype-Proteotype-Phenotype Relationships in Neurodegenerative Disease, (pp. 166). Berlin: Springer.
  • Halliday, G., Ophof, A., Broe, M., Jensen, P., Kettle, E., Fedorow, H., Cartwright, M., Griffiths, F., Shepherd, C., Double, K. (2005). α-Synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease. Brain, 128, 2654-2664. [More Information]

2004

  • Broe, M., Kril, J., Halliday, G. (2004). Astrocytic Degeneration Relates To The Severity Of Disease In Frontotemporal Dementia. Brain, 127(10), 2214-2220. [More Information]
  • Hodges, J., Davies, R., Xuereb, J., Casey, B., Broe, M., Bak, T., Kril, J., Halliday, G. (2004). Clinicopathological Correlates In Frontotemporal Dementia. Annals of Neurology, 56(3), 399-406. [More Information]
  • Kril, J., Halliday, G. (2004). Clinicopathological Staging Of Frontotemporal Dementia Severity: Correlation With Regional Atrophy. Dementia and Geriatric Cognitive Disorders, 17(4), 311-315. [More Information]
  • Huang, Y., Cheung, L., Rowe, D., Halliday, G. (2004). Genetic Contributions To Parkinson's Disease. Brain Research Reviews, 46(1), 44-70. [More Information]
  • Brooks, W., Kwok, J., Halliday, G., Godbolt, A., Rossor, M., Creasey, H., Jones, A., Schofield, P. (2004). Hemorrhage Is Uncommon In New Alzheimer Family With Flemish Amyloid Precursor Protein Mutation. Neurology, 63(9), 1613-1617.
  • Harding, A., Das, A., Kril, J., Brooks, W., Duffy, D., Halliday, G. (2004). Identification Of Families With Cortical Lewy Body Disease. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 128B (1), 118-122.
  • Henderson, J., Rodriguez, M., O'Sullivan, D., Pell, M., Fung, V., Benabid, A., Halliday, G. (2004). Partial Lesion Of Thalamic Ventral Intermediate Nucleus After Chronic High-Frequency Stimulation. Movement Disorders, 19(6), 709-711. [More Information]
  • Shepherd, C., Gregory, G., Vickers, J., Brooks, W., Kwok, J., Schofield, P., Kril, J., Halliday, G. (2004). Positional Effects Of Presenilin-1 Mutations On Tau Phosphorylation In Cortical Plaques. Neurobiology of Disease, 15(1), 115-119. [More Information]
  • Kersaitis, C., Halliday, G., Kril, J. (2004). Regional And Cellular Pathology In Frontotemporal Dementia: Relationship To Stage Of Disease In Cases With And Without Pick Bodies. Acta Neuropathologica, 108(6), 515-523. [More Information]
  • Kril, J., Hodges, J., Halliday, G. (2004). Relationship Between Hippocampal Volume And Ca1 Neuron Loss In Brains Of Humans With And Without Alzheimer'S Disease. Neuroscience Letters, 361(1-3), 9-12. [More Information]
  • Kril, J., Hodges, J., Davies, R., Du, N., Halliday, G. (2004). Survival In Frontotemporal Dementia. In B Vellas, LJ Fitten, B Winblad, H Feldman, M Grundman, E Giacobini (Eds.), Research and practice in Alzheimers disease, (pp. 215-219). Paris, New York: Springer.

2003

  • Kril, J., Patel, S., Harding, A., Halliday, G. (2003). Hippocampal neuron loss in vascular dementia and Alzheimer's disease. In B. Vellas, L. J. Fitten, B. Winblad, H. Feldman, M. Grundman & E. Giacobini (Eds.), Research and Practice in Alzheimers Disease, Volume 7, (pp. 199-203). NY: Springer Publishing Company.
  • Halliday, G., Double, K., Macdonald, V., Kril, J. (2003). Identifying severely atrophic cortical subregions in Alzheimer's disease. Neurobiology of Aging, 24(6), 797-806.
  • Double, K., Rowe, D., Hayes, M., Chan, D., Blackie, J., Corbett, A., Joffe, R., Fung, V., Morris, J., Halliday, G. (2003). Identifying the Pattern of Olfactory Deficits in Parkinson Disease Using the Brief Smell Identification Test. JAMA Neurology, 60(4), 545-549. [More Information]
  • Stanford, P., Shepherd, C., Halliday, G., Brooks, W., Schofield, P., Brodaty, H., Martins, R., Kwok, J., Schofield, P. (2003). Mutations in the tau gene that cause an increase in three repeat tau and frontotemporal dementia. Brain, 126(4), 814-826.
  • Morris, J., Hely, M., Halliday, G. (2003). Parkinsonism and Ageing. In Perminder s. Sachdev (Eds.), The Ageing Brain: The Neurobiology and Neuropsychiatry of Ageing, (pp. 275-282). Lisse, The Netherlands: Swets and Zeitlinger Publishers.
  • Schofield, E., Kersaitis, C., Shepherd, C., Kril, J., Halliday, G. (2003). Severity of gliosis in Pick's disease and frontotemporal lobar degeneration: tau-positive glia differentiate these disorders. Brain, 126(4), 827-840.
  • Broe, M., Hodges, J., Schofield, E., Shepherd, C., Kril, J., Halliday, G. (2003). Staging disease severity in pathologically confirmed cases of frontotemporal dementia. Neurology, 60(6), 1005-1011.
  • Harasty, J., Seldon, H., Chan, P., Halliday, G., Harding, A. (2003). The left human speech-processing cortex is thinner but longer than the right. Laterality: asymmetries of body, brain and cognition, 8(3), 247-260.

2002

  • Halliday, G., Ng, T., Rodriguez, M., Harding, A., Blumbergs, P., Evans, W., Fabian, V., Fryer, J., Gonzales, M., Harper, C., Pamphlett, R., Kril, J., et al (2002). Consensus neuropathological diagnosis of common dementia syndromes: testing and standardising the use of multiple diagnostic criteria. Acta Neuropathologica, 104(1), 72-78. [More Information]
  • Cordato, N., Pantelis, C., Halliday, G., Velakoulis, D., Wood, S., Stuart, G., Currie, J., Soo, M., Olivieri, G., Broe, G., Morris, J. (2002). Frontal atrophy correlates with behavioural changes in progressive supranuclear palsy. Brain, 125, 789-800.
  • Munch, G., Shepherd, C., McCann, H., Brooks, W., Kwok, J., Arendt, T., Hallupp, M., Schofield, P., Martins, R., Halliday, G. (2002). Intraneuronal advanced glycation endproducts in presenilin-1 Alzheimer's disease. NeuroReport, 13(5), 601-604.
  • Shepherd, C., McCann, H., Thiel, E., Halliday, G. (2002). Neurofilament-immunoreactive neurons in Alzheimer's disease and dementia with Lewy bodies. Neurobiology of Disease, 9(2), 249-257. [More Information]
  • Kril, J., Patel, S., Harding, A., Halliday, G. (2002). Neuron loss from the hippocampus of Alzheimer's disease exceeds extracellular neurofibrillary tangle formation. Acta Neuropathologica, 103(4), 370-376. [More Information]
  • Kril, J., Patel, S., Harding, A., Halliday, G. (2002). Patients with vascular dementia due to microvascular pathology have significant hippocampal neuronal loss. Journal of Neurology, Neurosurgery and Psychiatry, 72(6), 747-751. [More Information]

2001

  • Kril, J., Halliday, G. (2001). Alzheimer's disease: its diagnosis and pathogenesis. International Review of Neurobiology, 48, 167-217.
  • Nicholson, G., Spira, P., Sharpe, J., Halliday, G., Cavanagh, J. (2001). Clinical and pathological features of a Parkinsonian syndrome in a family with an Ala53Thr alpha-synuclein mutation. Annals of Neurology, 49, 313-319.
  • Harasty, J., Croot, K., Halliday, G., Xuereb, J., Bennett, H., Hodges, J. (2001). Cortical degeneration associated with phonologic and semantic language impairments in AD. Neurology, 56, 944-950.
  • Cordato, N., Halliday, G., McCann, H., Davies, L., Williamson, P., Fulham, M., Morris, J. (2001). Corticobasal syndrome with tau pathology. Movement Disorders, 16, 656-667.
  • Caine, D., Halliday, G., Patterson, K., Hodges, J. (2001). Sever anterograde amnesia with extensive hippocampal degeneration in a case of rapidly progressive frontotemporal dementia. Neurocase, 7, 57-64.

2000

  • Wong, D., Bishop, A., Lowes, M., Cooke, B., Barnetson, R., Halliday, G. (2000). Cytokine profiles in spontaneously regressing basal cell carcinomas. British Journal of Dermatology, 143(1), 91-98.
  • Stanford, P., Halliday, G., Brooks, W., Kwok, J., Storey, C., Creasey, H., Morris, J., Fulham, M., Schofield, P. (2000). Progresive supranuclear palsy pathology caused by a novel silent mutation in exon 10 of the tau gene: Expansion of the disease phenotype caused by tau gene mutations. Brain, 123, 880-893.

To update your profile click here. For support on your academic profile contact .